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ABSTRACT 
 
 Our genome is constantly challenged by sources that cause DNA 
damage.  To repair DNA damage and maintain genomic stability eukaryotes 
have evolved a complex network of pathways termed the DNA damage response 
(DDR).  The DDR consists of signal transduction pathways that sense DNA 
damage and mediate tightly coordinated reactions to halt the cell cycle and repair 
DNA with a collection of different enzymes.  In this manner, the DDR protects the 
genome by preventing the accumulation of mutations and DNA aberrations that 
promote cellular transformation and cancer development. Loss of function 
mutations in DDR genes and genomic instability occur frequently in many tumor 
types and underlie numerous cancer-prone hereditary syndromes such as 
Fanconi Anemia (FA).   
 My thesis research applies candidate-based and unbiased experimental 
approaches to investigate the role of several tumor suppressor genes (TSGs) in 
the DDR.  My dissertation will first describe a novel function for the breast and 
ovarian cancer tumor suppressor and FA-associated gene FANCJ in the DDR to 
ultraviolet (UV) irradiation.  In response to UV irradiation FANCJ supports 
checkpoint induction, the arrest of DNA synthesis, and suppresses UV induced 
point mutations.  Suggesting that FANCJ could suppress UV induced cancers, in 
sequenced melanomas from multiple databases I found somatic mutations in 
FANCJ previously associated with breast/ovarian cancer and FA syndrome.  
  The second part of my dissertation will describe an RNA interference 
   VI 
screen to identify genes modulating cellular sensitivity to the chemotherapeutic 
drug cisplatin.  The hereditary breast/ovarian cancer tumor suppressor BRCA2 is 
essential for DNA repair, thus BRCA2 mutant ovarian cancer cells are initially 
sensitive to cisplatin chemotherapy that induces DNA damage.  However, drug 
resistance develops and remains a major problem in the clinic.  My screen 
identified the chromatin remodeling factor CHD4 as a potent modulator of 
cisplatin sensitivity and predictor of response to chemotherapy in BRCA2 mutant 
cancers.  Taken together, my investigations highlight the important contribution of 
the DDR and the role they play in tumorigenesis and predicting therapeutic 
response. 
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CHAPTER I: INTRODUCTION 
 
 
Genomic Instability Underlies Cancer 
 
The notion that genomic instability is a common underlying defect for 
nearly all tumor cell types has been well appreciated and investigated for the 
latter half of the 20th century.  However, in 1902, the documentation of 
chromosome aberrations by German biologist Theodor Boveri nearly went 
unpublished as its own manuscript and was initially described in a footnote. 
Boveri doubly fertilized sea urchin eggs to induce multipolar mitoses and 
generated daughter nuclei that contained missing or additional chromosomes 
(Boveri 1902).  Sadly, his colleges felt that his findings would not lead to new 
areas of investigation, and thus, were not worthy of a separate publication.  
Unshaken, Boveri took it upon himself to continue his investigations and in 1914 
published Concerning the Origin of Malignant Tumours.  This became a visionary 
paper for its time describing the genetic basis of cancer and included the often 
quoted statement “malignant tumours might be the consequence of a certain 
abnormal chromosome constitution” (Boveri 1914).   
 
Boveri’s theory that cancer could arise from a single cell with scrambled 
chromosomes was correct and indeed spawned an entire field of investigation 
that has lasted nearly 50 years and continues to grow. Since Watson and Crick 
first solved the crystal structure of DNA, the field of genome instability has 
focused on investigating the factors that maintain the integrity of our genetic 
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material and how they are linked to cancer (Watson & Crick 1953).   The 
sequencing of the human genome and discovery of RNA interference has now 
given cancer biologists better tools to interrogate the factors that protect and 
repair our genome to suppress cancer.   
 
Although there are many hallmark characteristics of cancer cells, an 
unstable genome is persistently a common and essential defect (Hanahan et al. 
2000; Hanahan & Weinberg 2011).  The occurrence of additional cancer-like 
traits such as limitless growth potential, evasion of cell death, and tissue invasion 
and metastasis all depend on mutational events in the genome to incur such 
processes.  As such, cancer cells often display an increased mutation frequency 
in their genomes when compared to the genomes of normal healthy cells 
(Weinberg, 2007 p. 423-424).  However, as Boveri noted, cancer cells can also 
be unstable at the chromosomal level with additional copies of chromosomes, 
termed aneuploidy, or unstable due to loss of chromosome fragments or entire 
chromosomes themselves (Weinberg, 2007 pp. 11-13).  To make genomic 
instability even more complicated, DNA double strand breaks (DSBs) can occur 
on separate chromosomes and incorrectly fuse together to introduce 
chromosomal translocations.  These translocations are ubiquitous in cancer, 
especially in leukemia, where genes from separate chromosomes are fused 
together by translocation to create chimeric proteins that offer increased cellular 
fitness or even resistance to chemotherapy (Weinberg, 2007 pp. 109-115).  
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Taken together, genome instability contributes to the genetic aberrations required 
for cancer cell transformation and also serves to drive the disease to more 
advanced stages. 
 
Cancer is also frequently referred to as a “disease of aging”.  This means 
that the incidence of cancer increases within the older generations of the 
population.  This likely reflects that cancer is a complex disease that requires 
time for the accumulation of many genetic insults in the right combination for the 
cell to progress to a diseased state.  Exposure to environmental factors such as 
carcinogens in tobacco smoke or chimney soot can further contribute to the 
accumulation of mutations and shorten the period of time required for cellular 
transformation (Weinberg, 2007 pp. 400-402).  In addition, the genome is 
continuously challenged by non-environmental induced errors that arise as 
byproducts of normal cellular metabolism or DNA replication (Lindahl & Barnes 
2000).  When time is factored in, it has been estimated that the genome inside a 
mammalian cell can experience up to 105 spontaneous DNA lesions per day 
(Hoeijmakers 2009). 
 
The DNA Damage Response  
Our genome is constantly challenged by sources that cause DNA 
damage, yet genomic integrity must be maintained in order to dependably 
transmit our genetic material to our offspring and to protect us from cancer 
3
associated mutations that can compromise our own survival.  To cope with DNA 
damage and maintain genomic stability eukaryotes have evolved a complex 
interlocking network of pathways termed the DNA damage response (DDR).  
 
The DDR consists of signal transduction pathways that sense DNA 
damage or replication induced stress and mediate tightly coordinated responses 
to halt the cell cycle and repair DNA using a collection of different enzymes 
specific for the type of DNA damage incurred (Harper & Elledge 2007; Jackson & 
Bartek 2009; Ciccia & Elledge 2010). Proteins involved in DDR have traditionally 
been categorized as sensors, transducers, mediators, and effectors (Niida & 
Nakanishi 2006; Polo & Jackson 2011). The sensor proteins are responsible for 
recognizing damaged DNA and often directly recruit the transducer, mediator, or 
effector proteins to the lesions to propagate the DDR. I will now succinctly 
describe the best studied sensor, transducer, mediator, and effector proteins 
essential for the DDR. 
 
Sensors. Many sensor proteins have been investigated and characterized 
based on the types of DNA lesions that they recognize.  Proteins of the Mre11-
Rad50-Nbs1 (MRN) complex recognize and bind the ends of DNA double strand 
breaks (DSBs) through the DNA binding domain of MRE11 tethering the broken 
ends together (Lee & Paull 2005). Upon DNA binding, the architecture of the 
MRN complex is altered to promote inter-complex association from both DNA 
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ends and prevent intra-complex interaction (Moreno-Herrero et al. 2005). MRE11 
also contains DNA endonuclease and exonuclease activity that can facilitate 
DNA end processing, termed DNA resection, making the broken DNA a better 
substrate for other downstream repair factors (Williams et al. 2007).  
 
Adding to the complexity of sensing DNA DSBs, the Ku heterodimer (Ku70 
and Ku80) is a toroidal structure that can also rapidly bind to the ends of DNA 
DSBs (Mahaney et al. 2009).  Binding of the Ku heterodimer to DSBs prevents 
DNA end resection and promotes a more error prone repair pathway termed non-
homologous end joining (NHEJ), which will be further described later (Meek et al. 
2008; Mahaney et al. 2009).  
 
PARP1 and PARP2 are enzymes that act as molecular sensors for DNA 
DSBs, DNA single strand breaks (SSBs), abasic sites, and altered DNA bases 
such as 8-Oxo-Guanine or 3-Methyl-Adenine (Caldecott 2008).  Once bound to 
DNA, PARP1/2 catalyzes the addition of poly (ADP-ribose) sugar chains to 
histone proteins H1, H2B, and to PARP1 itself (Schreiber et al. 2006).  Histone 
PARylation by PARP1/2 is thought to recruit additional downstream factors that 
aid in the remodeling of chromatin at the site of damage (Polo et al. 2010; 
Schreiber et al. 2006; Chou et al. 2010).  
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Another dangerous threat to the genome that must be sensed are single 
stranded DNA (ssDNA) lesions that are instigated by replication fork stress and 
fork stalling.  Bulky DNA lesions encountered by the replication machinery can 
cause the arrest of leading strand synthesis and the formation of ssDNA regions 
due to the uncoupling of the replicative MCM helicase and DNA polymerase 
(Byun et al. 2005).  These ssDNA regions are immediately coated by the ssDNA 
binding protein RPA, which serves as a platform to generate a signaling cascade 
(Byun et al. 2005).  The RPA-ssDNA complex stimulates binding and activation 
of the RAD17-RFC2-5 DNA clamp loader which in turn recruits proteins of the 9-
1-1 complex (RAD9, RAD1, and HUS1) that initiate a signal transduction 
cascade to stabilize and repair the damage and eventually restart the replication 
fork (Paulovich et al. 1998; Ellison & Stillman 2003; Cimprich & Cortez 2008).  
 
Finally, the DNA mismatch repair (MMR) family of proteins serves to 
sense and recognize non-Watson-Crick base pairing (DNA mismatches) that 
result from misincorporated deoxyribonucleic acids (dNTPs).  The MMR family 
also senses erroneous insertion or deletion loops that form from replication errors 
(Kunkel & Erie 2005).  The MMR complex MSH2-MSH6 has been shown to 
continually scan DNA searching for errors and is unique in that it can discriminate 
between the parental and daughter strands of newly replicated DNA (Gorman et 
al. 2007).  Once MMR complexes detect damaged DNA a checkpoint response is 
mounted to halt the cell cycle and repair the error (Hsieh & Yamane 2008). 
6
 Transducers. Once the damage is recognized transducer kinases affect 
the activity of downstream mediator and effector proteins by regulating 
phosphorylation and dephosphorylation events.  Several transducer proteins of 
the phosphatidylinositol 3-kinase-like protein kinase (PIKKs) family, including 
Ataxia-Telangiectasia mutated (ATM) kinase, Ataxia-Telangiectasia and Rad-3-
related (ATR) kinase, and DNA Protein Kinase (DNA-PK) facilitate signal 
transduction pathways that trigger a tightly regulated response to stall the cell 
cycle and repair specific forms of damage (Ciccia & Elledge 2010).  Some 
crossover exists between these pathways, especially the ATM and ATR kinase 
pathways. When one pathway is partially or totally deficient that other pathway 
can stand in to trigger the signal transduction cascade (Bartek & Lukas 2003). 
 
The ATM kinase is initially recruited by the MRN sensor complex to DNA 
DSBs and has hundreds of protein substrates that amplify the DDR (Uziel et al. 
2003; Lee & Paull 2005; Lavin 2007).  The ATR kinase forms a complex with its 
binding partner ATRIP and is recruited to RPA-ssDNA nucleofilaments at sites of 
stalled replication forks or at RPA-ssDNA regions generated during DSB repair 
(Cortez et al. 2001; Rouse & Jackson 2002; Zou & Elledge 2003; Cimprich & 
Cortez 2008).  Lastly, the kinase DNA-PK is recruited by the Ku heterodimer to 
DNA DSBs and is more focused on the recruitment and regulation of proteins 
involved in DNA end joining to initiate an error prone NHEJ (Mahaney et al. 
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2009). DNA–PK complex members are also recruited to chromosomal ends 
known as telomeres, where they function in capping chromosome ends to 
prevent them from being mistaken for double-strand breaks (Burma & Chen 
2004). 
 
Effectors. Transducer kinases also phosphorylate effector kinases. The 
transducer kinase ATM activates the effector kinase CHK2 in response to DNA 
DSBs.  Similarly, the transducer kinase ATR activates the effector kinase CHK1 
in response to bulky DNA lesions or replication stress (Bartek & Lukas 2003; 
Shiloh 2003).  These effectors in turn spread the phosphorylation signal 
throughout the nucleus to amplify the DDR.   
 
The tumor suppressor protein p53 is a major downstream effector of the 
ATM/CHK2 DNA damage kinase pathway.  The p53 protein functions to induce 
cell cycle arrest, apoptosis, or senescence in response to genomic insults by 
transcriptionally regulating inhibitors of cyclin dependent kinases such as p21 
(Zhou & Elledge 2000; Meek 2004; Harris & Levine 2005).  When DNA damage 
occurs in normal cells, p53 dependent signaling promotes arrest in the G1 cell 
cycle phase by transcriptionally up-regulating p21 (Vogelstein et al. 2000).  This 
mechanism provides time to allow DNA repair and blocks entry into synthesis 
phase.   Additionally, p53 mediated up-regulation of p21 can block cells post 
replication in G2 phase in response to ionizing radiation (Bunz 1998).  
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Alternatively, if the DNA damage is too extensive p53 can up-regulate pro-
apoptotic genes such as BAX and PUMA to initiate cell death (Riley et al. 2008).  
It is therefore not surprising that p53 is commonly mutated in the majority of 
tumor types leading to loss of checkpoints and the evasion of cell death 
(Vogelstein et al. 2000). 
 
Mediators. Mediator proteins assist DNA damage signaling by fostering 
protein-protein interactions between components of the DDR, effector proteins, 
or with factors that promote the physical repair of the DNA lesion. A common 
feature of mediator proteins is BRCA1 carboxyl terminal (BRCT) domains, which 
function as protein-phosphoprotein interaction modules (Manke et al. 2003; Yu et 
al. 2003).  In response to DNA damage induced signaling, the mediator proteins 
help recruit the many physical repair pathways that evolved to cope with specific 
types of DNA damage.  I will briefly summarize the well characterized DNA repair 
pathways recruited to DNA damage by mediator proteins and the different forms 
of damage that they are best suited to repair.   
 
 In response to DNA SSBs or small base adducts such as alkylation 
products or oxidative damage the Base Excision Repair (BER) pathway is 
recruited.  BER is a multistep process that first removes the damaged bases from 
one strand of the DNA helix by excision and then replaces the excised backbone 
with newly synthesized DNA bases.  The poly (ADP-ribose) polymerase enzymes 
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PARP1 and PARP2 mentioned earlier in this section are essential sensors and 
signal transducers to initiate this process (Memisoglu & Samson 2000; David et 
al. 2007). 
 
In contrast, bulky single strand DNA lesions that distort the DNA helix, 
such as those created by ultraviolet (UV) irradiation, are processed by Nucleotide 
Excision Repair.  NER is traditionally classified into two sub-pathways, 
transcription-coupled NER, which is activated when the RNA polymerase 
encounters a DNA lesion, and global-genome NER, which is activated due to 
disrupted base pairing and general helix distortion.  These NER sub-pathways 
utilize different methods to detect lesions, however the mechanism of repair is 
very similar.  Like BER, the DNA surrounding the lesion on one strand is excised.  
The endonucleases XPF and XPG, which are mutated in the skin cancer prone 
disease Xeroderma Pigmentosa, are essential for this excision process.  The 
excised DNA is then filled in using the normal DNA replication machinery, namely 
polymerase delta, with the aid of additional DNA polymerases (de Boer & 
Hoeijmakers 2000; Gillet & Schärer 2006). 
 
At DNA lesions that stall replication forks, replication restart can leave 
ssDNA regions behind the replication fork.  These regions are repaired by either 
Translesion Synthesis (TLS) or error-free Post Replication Repair (PRR), which 
involves a template switching mechanism.  Both pathways are dependent on the 
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RAD6/RAD18 ubiquitin ligase complex (Branzei & Foiani 2010; Daigaku et al. 
2010; Karras & Jentsch 2010).  In error prone TLS, the high fidelity DNA 
replication polymerase is transiently replaced with one of several low fidelity 
polymerases that contain large active sites to accommodate the lesion and 
bypass the DNA damage.  In the error free PRR template switching mechanism, 
the single stranded DNA gap generated during replicative bypass is repaired by 
strand invasion of the sister chromatid which is used as a template for repair 
(Budzowska & Kanaar 2009). TLS and PRR are both dependent on 
RAD6/RAD18 mediated monoubiquitination or polyubiquitination, respectively, on 
lysine 63 of the replicative clamp PCNA (Ulrich & Walden 2010). 
 
The repair of DNA DSBs is more complicated in that several repair 
pathways have evolved to cope with this type of damage.  The pathway of choice 
is mainly influenced by the cell cycle phase and the extent of DNA end 
processing.  DNA end joining promoted by the Ku heterodimer or PARP proteins 
proceeds with minimal DNA end processing, is error prone, and typically occurs 
in G1 phase of the cell cycle prior to duplication of the genome.  In classical 
NHEJ, Ku immediately localizes to DSBs where it recruits and activates the 
catalytic subunit of DNA-PK.  DNA-PK stabilizes DNA ends and prevents 
resection allowing recruitment of XRCC4/LIG4 which promotes the re-ligation of 
broken ends with the help of ARTEMIS and the stimulatory factor XLF (Meek et 
al. 2008; Mahaney et al. 2009). In alternative NHEJ (also known as 
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microhomology-mediated end joining), which is a backup pathway to classical 
NHEJ, the PARP proteins compete with Ku at broken DNA ends to promote 
limited end resection (~5-25 nucleotides) and repair DNA by a mechanism that is 
similar to homologous recombination which is described next (Wang et al. 2006).  
 
DNA DSBs recognized by the MRN sensory complex activate the signal 
transduction kinase ATM to process the DNA surrounding the break and promote 
error free repair by homolgous recombination (HR) (Williams et al. 2007).  HR 
mainly occurs during S and G2 phases of the cell cycle and is a conservative 
process in that it uses a sister chromatid as a template for repair.  The first step 
in HR is the nucleolytic processing of DNA ends by the MRN complex and other 
enzymes such as the exonuclease EXO1, to promote 5’ to 3’ DNA end resection 
(Bernstein & Rothstein 2009; Rupnik et al. 2010).  The remaining 3’ ssDNA 
overhangs are coated by RPA and then replaced by RAD51 in a manner directed 
by the breast cancer associated protein BRCA2.   Recent papers describing the 
purification and biochemical analysis of BRCA2 have shed light on this critical 
step in HR (Jensen et al. 2010; Liu et al. 2010; Jensen 2013).  The RAD51 
nucleoprotein filament then initiates a homology search on the sister chromatid 
and promotes DNA strand invasion forming a D-loop structure.  DNA 
polymerases then synthesize new DNA using the sister chromatid as a template 
and ligases, helicases, and resolvase enzymes mediate the cleavage and 
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resolution of HR intermediates to yield repaired DNA molecules (Mazón et al. 
2010).  
 
To repair DNA adducts that covalently crosslink the two strands of DNA 
together and impede replication machinery cells have evolved the Fanconi 
anemia (FA) pathway.  FA was named after the Swiss pediatrician, Guido 
Fanconi, that discovered the rare, primarily recessive genetic disorder that 
renders cells extremely sensitive to DNA crosslinking agents such as Cisplatin or 
Mitomycin C (Moldovan & D’Andrea 2009).  The FA pathway consists of at least 
16 gene products and is divided into two complexes. Upstream FA proteins are 
required for the monoubiquitination events of FANCD2 and FANCI proteins, and 
downstream FA proteins which are not required for ubiquitination, but function at 
the chromatin level to properly excise the crosslink and restore the DNA using a 
combination of template switch and HR dependent DNA repair mechanisms 
previously described (Moldovan & D’Andrea 2009; Kottemann & Smogorzewska 
2013).  
 
Adding another layer of complexity to DNA repair is the orderly 
progression of pathway choice.  While the type of lesion or DNA substrate 
provides some specificity for pathway choice this can also be accomplished by 
negative regulation of one repair pathway by another.  For example, ATM 
dependent processing at DNA DSBs that promotes DNA end resection during 
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HR can be inhibited by the NHEJ factor 53BP1 (Bunting et al. 2010).  53BP1 is 
thought to encourage NHEJ by stabilizing broken DNA ends and increasing their 
ability to detect and ligate to one another (Difilippantonio et al. 2008; Dimitrova et 
al. 2008).  In cancer cells with mutations in the breast cancer associated protein 
BRCA1 which display defects in the resection step of HR, chromosomes are 
aberrantly joined into complex re-arrangements due to the function of pro-NHEJ 
factors 53BP1 and LIG4.  Depletion of 53BP1 in these cells restores DNA end 
resection and thus partially restores HR (Cao et al. 2009; Bunting et al. 2010; 
Bouwman et al. 2010).  This suggests that in normal cells BRCA1 can compete 
with and overcome 53BP1 function at DNA DSBs to allow DNA end resection 
and promote high fidelity HR mediated repair. 
 
In addition to BRCA1 mutant cells, it has been demonstrated that the 
genetic instability and sensitivity of FA cells to DNA crosslinking agents is also 
due to aberrant NHEJ (Adamo et al. 2010; Pace et al. 2010).  This could suggest 
that FA proteins normally promote HR and suppress NHEJ, however not all 16 
FA proteins have been examined for this function.  Taken together, these 
observations reveal that in the absence of appropriate repair pathway choice, 
incorrect pathways can be utilized and cause detrimental outcomes resulting in 
genomic instability and ultimately cancer.  
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The DDR and Chromatin 
 Although the DDR has been well characterized at the DNA level, it is 
important to consider the DDR within the context of chromatin.  Unlike 
programmed events such as replication of the genome in S phase, the DDR must 
be elicited at any point in time in response to genomic insult and must over come 
the physical barriers that are associated with chromatin structure.  Chromatin 
comprises DNA wrapped around histone proteins and also associates with a 
variety of non-histone proteins that facilitate the higher order structure 
organization of the genome allowing it to compact into the nucleus (Kornberg 
1977; Probst et al. 2009; Li & Reinberg 2011).  
 
The fundamental unit of chromatin is the nucleosome which contains DNA 
wrapped around a histone octamer composed of a histone (H3-H4)2 tetramer 
surrounded by two histone H2A-H2B dimers (Luger et al. 2012).  The presence 
of linker DNA serves to connect adjacent particles and associates with linker 
histones (Happel & Doenecke 2009). The composition of nucleosomes in 
chromatin can vary due to histone posttranslational modifications or the 
existence of histone variants (Probst et al. 2009).  Over the last decade, a 
collection of studies have demonstrated the importance of these modules whose 
configuration and spatial organization are a source of information storage for the 
cell contributing to cellular functions and identity.  
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DNA repair and signaling machineries must work in concert with 
chromatin-associated elements in order to access and repair DNA damage.  
There are two well studied classes of enzymes that facilitate this process, (1) 
enzymes that modify histones and (2) ATP-dependent chromatin remodeling 
enzymes.  Histone modifying enzymes function by posttranslationally modifying 
residues within the tail of histones or by modifying histone binding proteins.  
These modifications include phosphorylation, acetylation, methylation, poly(ADP-
ribosylation), ubiquitination, or SUMOylation in addition to other less studied 
modifications.  These modifications can alter the arrangement of nucleosomes, 
but more typically serve as a signal or code that recruits proteins to chromatin, 
especially in response to DNA damage (van Attikum & Gasser 2009).  
  
 Chromatin remodeling enzymes function to slide nucleosomes along DNA, 
promote general nucleosome metabolism by exchanging histones or histone 
dimers, or evict nucleosomes from chromatin altogether (Clapier & Cairns 2009).   
All chromatin remodeling complexes in the SWI2/SNF2 family contain catalytic 
subunits with an ATPase/helicase domain.  Distinct functional motifs within the 
catalytic subunit, but outside of the ATPase/helicase domain, determine the 
classification of chromatin remodelers into four subfamilies including SWI/SNF, 
ISWI, CHD, and INO80 (Clapier & Cairns 2009).  Each subfamily of chromatin 
remodelers contains specific affinity for different histone or nucleosome 
modifications.  For instance, the SWI/SNF subfamily contains a bromodomain 
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that binds acetylated histone tail residues.  The ISWI subfamily contain HAND, 
SANT, and SLIDE domains that specifically bind DNA wrapped around 
nucleosomes.  The CHD subfamily contain tandem chromodomains that have 
affinity for methylated histones and lastly, while the INO80 subfamily does not 
have a specific domain to bind modified histones, they contain a unique insertion 
within their ATPase domain (Clapier & Cairns 2009).  
  
 I will now highlight some of the cornerstone discoveries and recent 
findings that have enabled a better understanding of the DDR within the context 
of chromatin.  I will discuss the key roles of histone modifications and chromatin 
remodeling factors and for clarity focus on the DDR to DNA DSBs. 
  
 The first histone modification discovered that was induced by DNA 
damage was the ATM dependent phosphorylation of the histone variant H2A.X 
(Rogakou et al. 1998).  H2A.X is immediately phosphorylated in response to 
DNA DSBs and is often used as a nuclear marker of DNA damage.  This H2A 
variant is different between species, but its DNA damage induced 
phosphorylation, commonly referred to as γH2A.X, is conserved highlighting the 
importance of this modification in the DDR.  The role of γH2A.X is primarily to 
coordinate and spread DDR induced signals.  At DNA DSBs, γH2A.X recruits 
mediator of DNA damage checkpoint protein 1 (MDC1), which itself is targeted 
by several protein kinases including ATM (Jungmichel & Stucki 2010).  ATM then 
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promotes spreading of γH2A.X to neighboring nucleosomes.  γH2A.X can also 
be induced in response to replication stress.  In this situation MDC1 promotes 
expansion of γH2A.X by recruiting the adapter protein TOPBP1, which binds and 
activates ATR at stalled replication forks (Wang et al. 2011).  In either event 
bidirectional spreading of γH2A.X contributes to checkpoint amplification and 
defines chromatin regions where the DDR is confined (Yuan et al. 2010).   
Exactly how this confinement is achieved is still an active area of investigation.  
One possibility is that some chromatin regions are more accommodating to 
γH2A.X, while others, especially condensed heterochromatic regions, are not 
permissive (Kim et al. 2007).  Several phosphatases have been implicated in the 
dephosphorylation of γH2A.X, namely PP2ACα, PP2ACβ, PP4C, PPC6, and 
WIP1 in mammals.  Depletion of these phosphatases inhibits γH2A.X removal, 
DNA DSB repair, and increases cellular sensitivity to irradiation (Keogh et al. 
2006; Chowdhury et al. 2008; Douglas et al. 2010; Nakada et al. 2008; Macůrek 
et al. 2010; Cha et al. 2010).  
 
 H2A and its variant H2A.X can also be ubiquitinated at DNA DSBs by the 
E3 ubiquitin ligases RNF8 and RNF168 using a non-proteasomal lysine (K63) 
based linkage (Kolas et al. 2007; Huen et al. 2007; Mailand et al. 2007; Pinato et 
al. 2009; Stewart et al. 2009; Doil et al. 2009).  This occurs with the help of the 
E2 ubiquitin conjugating enzyme UBC13 (Kolas et al. 2007; Zhao et al. 2007).   
The RNF8/RNF168-dependent K63 ubiquitin chains on H2A histones are binding 
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substrates for RAP80, which forms a complex with BRCA1, BRCC36, ABRAXAS, 
and MERIT (Wang et al. 2007).  RAP80 binding to BRCA1 has been shown to 
limit CtIP-BRCA1 binding at broken DNA ends, inhibiting DNA end resection and 
HR (Coleman & Greenberg 2011; Hu et al. 2011).  On the contrary, others have 
shown that the RNF8/RNF168 ubiquitin cascade can promote ubiquitin 
dependent loading of RAD18 and RAD51C to DSBs to instead promote repair by 
HR (Huang et al. 2009).  Thus, while the RNF8/RNF168 ubiquitin cascade 
coordinates the ordered recruitment of DNA repair factors to DSBs, how 
specificity and pathway choice is achieved in this context remains to be 
determined.  The deubiquitinating (DUB) enzyme OTUB1 could provide a layer of 
specificity in this pathway.  Alternative to its DUB cleavage activity, OTUB1 
negatively regulates RNF168 mediated K63 ubiquitin linkages by directly binding 
to the E2 UBC13 preventing the interaction between UBC13/RNF168 and 
inhibiting ubiquitination (Nakada et al. 2010; Wiener et al. 2012; Sato et al. 2012). 
 
 Alternative to ubiquitination, histone methylation at nucleosomes is 
controlled by histone methyltransferases (HMTs).  These enzymes contain 
catalytic SET domains that transfer methyl groups from S-adenosylmethione, an 
important methyl donor for many metabolic reactions in the cell, to specific 
arginine or lysine residues on histones.  One important methylation moiety 
enriched at DNA DSBs is H3K36me2, which is mounted by the HMT Metnase.  
H3K36me2 is required for the accumulation of both sensor proteins NBS1 and 
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Ku70 at DSBs where it promotes DNA repair by NHEJ (Fnu et al. 2011). 
Alternatively, the removal of methylation marks from histones can serve to 
regulate repair at DNA DSBs by pausing transcription and promoting DNA repair.  
The histone methyl mark H3K4me3 is normally required for transcriptional 
activation, but is removed in response to DSBs by the demethylase JARID1A 
(Seiler et al. 2011).  This process is thought to promote transcriptional silencing 
in cis at chromatin associated with DNA DSBs to allow DNA repair.  
  
 Acetylation is another posttranslational modification that regulates DNA 
repair in the context of chromatin.  Several subunits of the mammalian SWI/SNF 
remodeling complex and the acetyltransferase TIP60 are recruited to DNA DSBs 
where they locally decrease nucleosome stability (Xu & Price 2011; Murr et al. 
2006). TIP60 directly acetylates ATM, histones H2A/H2A.X, and H4 in response 
to DNA damage and is required for DNA DSB repair (Gorrini et al. 2007; Murr et 
al. 2006; Bird et al. 2002; Sun et al. 2005; Sun et al. 2010; Kusch et al. 2004).  
The enzymatic activity of both SWI/SNF and TIP60 is essential for the 
downstream steps of DSB repair including histone ubiquitination and the 
recruitment of mediator proteins BRCA1 and 53BP1 (Xu & Price 2011; Murr et al. 
2006). 
 
 Lastly, the nucleosome remodeling complex (NuRD) has been shown to 
function in DNA DSB repair by orchestrating several posttranslational 
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modifications with chromatin remodeling. The catalytic subunits of the NuRD 
complex are chromodomain proteins CHD3 and CHD4. These subunits are 
mutually exclusive and associate with the histone deacetylases HDAC1 and 
HDAC2 to couple histone deacetylation with chromatin remodeling (Lai & Wade 
2011). It is important to note that expression of several NuRD complex 
components was shown to be reduced in patient cells from the progeria 
Hutchinson-Gilford syndrome and from naturally aged cells (Pegoraro et al. 
2009).  Reduced expression of these subunits corresponded with increased 
γH2A.X expression, a histone marker of DNA damage described previously, and 
with loss of heterochromatic structures.  These findings suggest that the NuRD 
complex could prevent the accumulation of DNA damage by maintaining higher 
order chromatin structures.  Furthermore, many NuRD complex members 
accumulate in foci at sites of DNA damage and several members associate with 
the central DDR kinase ATR (Chou et al. 2010; Larsen et al. 2010; Smeenk et al. 
2010; Polo et al. 2010; Goodarzi et al. 2011).  
 
 Interestingly, several studies have shown that NuRD subunits CHD3 and 
CHD4 have distinct roles in the DDR to DNA DSBs.  CHD4 was shown to be 
targeted by the kinase ATM, but this phosphorylation event was not required to 
recruit CHD4 to sites of laser induced DNA DSBs (Matsuoka et al. 2007; Polo et 
al. 2010; Urquhart et al. 2011).  CHD4 was also shown to be recruited to DSBs in 
a manner dependent on PARP activity and was demonstrated to bind PAR 
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moieties in vitro even though it does not contain a PAR binding domain (Polo et 
al. 2010).  CHD4 also interacts with the FHA domain of the ubiquitin ligase RNF8 
and has been shown to locally decondense chromatin at DSBs with RNF8 
allowing for damage induced ubiquitination by RNF8/RNF168 and downstream 
recruitment of BRCA1 and 53BP1 (Larsen et al. 2010; Smeenk et al. 2010; 
Luijsterburg et al. 2012).  In stark contrast, CHD3 is thought to function as an 
inhibitor of DNA DSB repair specifically in heterochromatin.  Inhibiting the 
repressive actions of CHD3 on heterochromatin was shown to facilitate 
chromatin decondensation and promote a DDR.   CHD3 interacts with the 
constitutively SUMOylated form of the Krüppel-associated box repression 
(KRAB) domain containing protein KAP-1 (also known as TRIM28).  However, in 
response to DNA damage ATM phosphorylates KAP-1 and this modification 
disrupts its interaction with CHD3 to induce heterochromatin relaxation (Goodarzi 
et al. 2008; Goodarzi et al. 2011).  Depletion of the heterochromatin factors 
HDAC1, HDAC2, and HP1 alleviate the requirement for ATM at heterochromatin 
associated DSB repair (Goodarzi et al. 2008).  Heterochromatic phospho-KAP-1 
focus formation and subsequent decondensation was also shown to be 
dependent on MDC1, RNF8, RNF168, and 53BP1.  53BP1 spatially concentrates 
the MRN sensory complex at late repairing heterochromatic DNA DSBs to 
enhance ATM activity and presumably allows repair by NHEJ (Noon et al. 2010). 
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 It is clear from the above overview that a complex arrangement of histone 
modifications and remodeling of chromatin is required for proficient DNA damage 
induced signaling and repair (Figure 1-1, general model).  Some complexes have 
been implicated in specific repair events or are required for the subsequent 
accumulation of additional repair factors.  The specificity of these factors for 
histone modifications and function in altering nucleosome occupancy at DNA 
surrounding DSBs still remains an active area of investigation.  Future studies 
using multidisciplinary approaches combining quantitative proteomics and 
microscopy techniques could enable a better understanding of chromatin 
dynamics in response to DNA damage and determine the interdependency of 
different remodeling complexes.  
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Figure 1-1 General schematic of the DNA damage response 
in the context of chromatin. The dynamics of proteins involved 
in the of DNA damage response are depicted. DNA damage 
checkpoint and repair factors are recruited (green arrows), while 
modulators of chromatin organization and general proteins that 
compose chromatin operate in both directions (Orange arrows). 
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DNA 
 Damage 
Loss of Function in the DDR, Cancer Development, and Targeted Therapies 
 Highlighted in the first section of this introduction is the characteristic that 
human tumors are genetically unstable (Hanahan & Weinberg 2011).  
Inactivation of DDR genes enhances the accumulation of mutations and DNA 
aberrations that promote transformation and cancer development.  This is 
evident based on the cancer-prone phenotypes of several DDR syndromes. I will 
describe some of these syndromes as well as the potential therapeutic avenues 
that could be exploited due to inherent DNA repair defects of these cells. 
  
Lynch syndrome, also known as hereditary non-polyposis colon cancer 
(HNPCC), results from inherited heterozygous mutations in the DNA MMR genes 
MLH1, MSH2, MSH6, and PMS2 (Spry et al. 2007).  Mutations in these genes 
can also predispose the development of cancers in the endometrium, ovary, 
stomach, and kidneys (Lynch et al. 2009).  One form of genomic instability 
associated with HNPCC is the expansion or contraction of repetitive 
microsatellite DNA sequences termed microsatellite instability (MSI) (Lynch et al. 
2009).  However, some HNPCC-associated mutations have unknown 
pathogenicity and do not present with MSI.  Our laboratory recently uncovered 
one such example by investigating an MLH1 clinical mutation with a leucine (L)-
to-histidine (H) amino acid change at position 607 that ablated MLH1 binding to 
the Fanconi anemia-associated protein FANCJ (Xie et al. 2010).  Instead of 
directly promoting MSI, loss of MLH1 binding to FANCJ altered MMR signaling in 
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response to DNA damaging.  Importantly, loss of MLH1 binding to FANCJ 
provided insight towards directed therapy as loss of the interaction uniquely 
sensitized cells to DNA cross-linking chemotherapies (Xie et al. 2010).  Other 
therapies have exploited defects arising from MMR deficiency rather than 
exploiting defects arising from specific mutations in MMR proteins. The inhibitor 
of DNA base synthesis, methotrexate, has been demonstrated to uniquely kill 
MMR-deficient cells by promoting the accumulation of oxidative lesions (Martin et 
al. 2010).  Furthermore, depletion studies showed that loss of the BER 
polymerase Polβ or the mitochondrial polymerase Polγ resulted in synthetic 
lethality in combination with MSH2 and MLH1 deficient tumor cells, again owing 
to an increased frequency of oxidative lesions (Martin et al. 2010).  Further 
assessment of these therapeutic avenues will be important, especially given that 
many sporadic forms of colon cancer also contain loss of function mutations in 
MMR genes (Liu et al. 1995). 
 
Familial forms of breast, ovarian, and pancreatic cancer are also linked to 
defects in HR pathway associated genes such as BRCA1, BRCA2, 
FANCJ/BACH1, PALB2, and RAD51C (Miki et al. 1994; Wooster et al. 1995; 
Walsh & King 2007; Levy-Lahad 2010; Cantor & Guillemette 2011).  Patients with 
BRCA2 mutations also show increased incidence of male breast, pancreatic, and 
prostate cancer (Moynahan & Jasin 2010).  Additionally, inactivation of the ATM 
dependent signaling axis in cancer has become apparent as mutations in CHK2, 
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ATM, NBS1, and RAD50 are all associated with a 2-fold increased risk of 
developing breast cancer (Walsh & King 2007).  In patients with BRCA1 or 
BRCA2 mutant tumors the therapeutic use of PARP inhibitors has been an active 
area of investigation (Jackson & Bartek 2009).  Screening of chemical libraries 
and the chemical refinement of compounds identified have already led to the 
third generation of PARP inhibitors currently in use in clinical trials for BRCA 
patients (Rouleau et al. 2010; Lord & Ashworth 2012).  The synthetic lethality of 
PARP inhibition in patients with BRCA mutations has been proposed to result 
from the accumulation of unrepaired DNA breaks or from the inhibition of PARP 
release from a DNA lesion (Rouleau et al. 2010).  In either event, both types of 
DNA lesions would contribute to the collapse or stalling of replication forks, which 
could increase the number of DNA DSBs in the genome.   In normal BRCA1/2 
wild-type cells the effect of PARP inhibition is buffered by active homologous 
recombination, which repairs DNA DSBs.   
 
The strong link between familial breast and ovarian cancer with FA 
syndrome has also become apparent (Levy-Lahad 2010).  Mono-allelic 
inheritance of mutations in BRCA2, FANCJ/BACH1, and PALB2 predispose to 
breast and ovarian cancer as described previously, however, bi-allelic inheritance 
of these genes results in FA syndrome within the complementation groups FA-
D1, FA-J, and FA-N, respectively.  Most recently, bi-allelic mutations in RAD51C 
were also identified in an FA-like disorder (Levy-Lahad 2010; Vaz et al. 2010).  
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 Not surprisingly, FA cells have underlying genomic instabilities showing 
spontaneous and DNA crosslinker induced chromosome fragility, a hallmark that 
is important for diagnosis in patients.  FA patients are also associated with an 
increased risk of pre-leukemic syndromes and cancer including myelodysplasia 
(MDS) and acute myeloid leukemia (AML) (Bagby & Meyers 2007; Dokal & 
Vulliamy 2008; Quentin et al. 2011).  FA patients typically undergo progressive 
bone marrow failure (BMF) during childhood, which requires allogeneic 
hematopoietic stem cell (HSC) transplant (Gluckman & Wagner 2008; 
Shimamura & Alter 2010).  Most attempts to uncover the mechanisms leading to 
BMF in FA patients have been unsuccessful due to difficulties associated with 
studying a rare human disease with low bone marrow cells and because the 
mouse model of FA does not fully recapitulate the phenotypes of human FA 
(Parmar et al. 2009).  Recent work analyzing a large series of primary bone 
marrow samples from FA patients in functional models revealed that 
hematopoietic stem and progenitor cells (HSPCs) from these patients are 
impaired due to exacerbated p53/p21 activation and G0/G1 cell cycle arrest 
activated by the intrinsic DNA repair defect (Ceccaldi et al. 2012).  Depletion of 
p53 in this study rescued the HSPC defects and colongenic ability in several 
models, which implies that targeting p53 could have therapeutic potential to 
prevent BMF in FA patients.  However, while the direct targeting of p53 with 
small molecule inhibitors could likely enhance HSPC progression and mitigate 
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BMF, this approach would also likely enhance genomic instability and increase 
the risk of clonal evolution encouraging malignancy (Gudkov & Komarova 2010).  
Perhaps a better approach to ameliorate BMF in FA patients could come from 
the use of new drugs that inhibit pro-inflammatory cytokines or oxidative stress 
as the induction of p53/p21 can arise from excess cellular stress or from 
unresolved DNA damage (Dufour & Svahn 2008).  
 
In summary, the proper coordination and fidelity of DNA repair processes 
is essential for development and for suppressing cellular transformation.  Defects 
in the DDR not only predispose to certain types of cancer as described in this 
section (Table 1-1), but can also alter the sensitivity of tumor cells to therapies 
that target specific aspects of the DDR.  
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Disease Gene(s) 
Mutated 
DDR Defect Cancer 
Type 
Hereditary 
NonPolyposis 
Colorectal Cancer 
(HNPCC) also 
called Lynch 
Syndrome 
MSH2, 
MSH3, 
 MSH6, 
MLH1, 
PMS2 
DNA Mismatch 
repair 
Colorectal, 
Ovarian, 
Endometrial cancer  
Familial Breast/ 
Ovarian cancer 
ATM, 
BRCA1, 
BRCA2, 
FANCJ, 
CHK2, 
NBS1, 
PALB2, 
RAD50, 
RAD51C 
Homologous 
recombination, 
DNA Damage  
Signaling 
 
Breast cancer, 
Ovarian cancer 
 Fanconi anemia 
(FA) 
FANCA-C, 
FANCD1, 
D2, 
FANCE-G, 
FANCI, J, 
L-Q 
Interstrand 
crosslink repair, 
Homologous 
recombination 
Acute myeloid 
leukemia, 
Myelodysplasia, 
Squamous cell  
carcinoma 
Table 1-1 Human genetic diseases associated with defects 
in DNA damage response (DDR) genes and associated 
cancer types.  
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Concluding Remarks 
 To combat sources of DNA damage cells have evolved many complex 
pathways collectively known as the DDR. The DDR consists of signal 
transduction pathways that sense DNA damage and mount tightly coordinated 
responses to pause the cell cycle and repair DNA.  An arsenal of different 
enzymes specific for the type of DNA damage induced is employed in concert 
with enzymes that modify histones and ATP-dependent enzymes that remodel 
chromatin to access the damage. The inactivation of genes associated with the 
DDR causes the accumulation of mutations and DNA aberrations that promote 
transformation and cancer development.  As a result, one common characteristic 
for all human tumors is genetic instability.   
 
For my first thesis investigation, I chose to characterize the function of the 
breast/ovarian cancer tumor suppressor and Fanconi Anemia associated protein 
FANCJ, in a role that has not previously been implicated for this protein, the DDR 
to ultraviolet (UV) irradiation.  FANCJ is best known for its function with BRCA1 
in response to DNA double strand breaks and for its function in DNA interstrand 
crosslink repair with the FA pathway (Cantor et al. 2001; Litman et al. 2005).  I 
found that FANCJ is recruited to sites of UV induced DNA damage in a manner 
dependent on MMR factors and dual incision by NER endonucleases XPF and 
XPG in S-phase of the cell cycle. Surprisingly, BRCA1 binding was not required 
for FANCJ localization to sites of damage. In response to UV irradiation FANCJ 
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supports checkpoint induction, the arrest of DNA synthesis, and suppresses UV 
induced point mutations.  Despite these findings I noted that FANCJ deficient 
cells were not sensitive to UV induced DNA damage and thus considered if 
FANCJ loss could be associated with tumorigenesis in skin cells. In sequenced 
melanomas I found somatic mutations in FANCJ that were previously associated 
with hereditary breast cancer and cancer prone FA.  
 
In the second part of my thesis research I investigate the factors that 
contribute to chemo-resistance in BRCA2 mutant ovarian cancers.  As described 
in the second part of my introduction BRCA2 mutant tumors have defects in DNA 
repair by HR and are thus initially sensitive to DNA damage inducing 
chemotherapies.  However, ovarian tumors are typically asymptomatic and 
diagnosed at more advanced stages, thus therapeutic resistance eventually 
develops. One mechanism of resistance includes reversion mutations in BRCA2 
that restore functional protein and RAD51-based HR (Sakai et al. 2008; Sakai et 
al. 2009; Edwards et al. 2008).  It is unknown how chemo-resistance develops 
without reversion mutations.  Here, I found in a genome-wide shRNA screen, that 
depletion of the chromatin-remodeling factor CHD4 confers cisplatin resistance in 
BRCA2 mutant cells. Rescue by CHD4 depletion does not improve RAD51 foci 
formation and occurs through a novel mechanism. Consistent with CHD4 
modulating therapeutic response, I discovered that low CHD4 expression 
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correlates with poor response and shortened overall survival in patients with 
BRCA2-mutant ovarian tumors.  
 
These two studies help to better understand the roles of DDR pathways 
and chromatin remodeling factors in the suppression of UV-induced mutations 
and treatment of ovarian tumors with chemotherapy, respectively. Both 
discoveries contribute to our understanding of the DDR and its relationship with 
hereditary cancers. 
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CHAPTER II:  
 
FANCJ FUNCTION IN THE DNA DAMAGE RESPONSE TO UV IRRADIATION 
 
Preface 
 
 
 This research chapter derives from work I started in my first year in 
Sharon Cantor’s lab in February of 2008 and lasted until December of 2013 when 
it was published in the journal Cancer Research entitled “FANCJ Localization by 
Mismatch Repair is Vital to Maintain Genomic Integrity after UV Irradiation”.  I am 
the first author of this publication with additional authors Amy Branagan, Min 
Peng, Aashana Dhruva, Orlando Scharer, and Sharon Cantor. 
 
 This work originally stemmed from work I completed to help former lab 
members Jenny Xie, Rachel Litman, and Shu Wang produce the Oncogene 
publication “Targeting the FANCJ-BRCA1 Interaction Promotes a Switch from 
Recombination to Pol Eta-Dependent Bypass” for which I am third author.  
During that time Min and myself recognized that FANCJ accumulated in nuclear 
foci in response to UV irradiation.  I also performed mutation frequency assays in 
cells in response to various DNA damaging agents and found that loss of FANCJ 
significantly elevated the frequency of mutations in response to UV irradiation.  
Together, these findings ultimately set me on the path to functionally investigate 
the role of FANCJ in the DDR to UV irradiation. 
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 In this data chapter, I performed all the technical experiments with the help 
of Min Peng retrovirally complementing the patient derived FA-J cells with 
various FANCJ mutant species.  Shu Wang performed the GFP-Pol Eta foci 
experiments, Amy Branagan performed the FACs based RPA phosphorylation 
assay analyzing the UV induced checkpoint, and Aashana Dhruva aided in lysate 
preparation and running SDS-PAGE gels for experiments depleting MMR 
proteins.  Microscopy experiments were analyzed double blind with the essential 
help of many undergraduates and high school students who volunteered over the 
course of several summers with a special internship program through Bancroft 
High School.  The model drawn in Figure 2-28 was initially designed by graphic  
artist Miroslav Koulnis hired by Sharon Cantor, but the many alterations and 
modifications to this drawing achieved in the final model were done by myself. 
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Abstract 
 
Nucleotide excision repair (NER) is critical for the repair of DNA lesions 
induced by ultraviolet (UV) radiation, but its contribution in replicating cells is less 
clear. Here, we show that dual incision by NER endonucleases including XPF 
and XPG promotes the S-phase accumulation of the BRCA1 and Fanconi 
anemia (FA)-associated DNA helicase FANCJ to sites of UV-induced damage.  
At these sites, FANCJ promotes RPA phosphorylation and the arrest of DNA 
synthesis following UV irradiation. Interaction defective mutants of FANCJ reveal 
that BRCA1 binding is not required for FANCJ localization, whereas interaction 
with the mismatch repair (MMR) protein MLH1 is essential. Correspondingly, we 
find that FANCJ, its direct interaction with MLH1, and the MMR protein MSH2 
function in a common pathway to ensure NER-dependent and independent S-
phase checkpoints.  Further supporting an important role for FANCJ in the 
response to UV irradiation, FANCJ suppresses UV induced point mutations. In 
combination with the fact that FANCJ deficient cells are not sensitive to killing by 
UV light, we considered that FANCJ loss could be associated with tumorigenesis.  
Along these lines, in melanoma we found somatic mutations in FANCJ expected 
to inactivate the ATPase/helicase activity that were previously associated with 
hereditary breast cancer and FA. Thus, we propose collaborations between FA, 
NER and MMR are necessary to initiate checkpoint activation in replicating 
human cells to limit genomic instability.   
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Introduction 
 
Repair of ultraviolet (UV) irradiation-induced DNA damage depends on the 
nucleotide excision repair (NER) pathway.  Underscoring the essential role of 
NER in repair of UV-induced DNA damage, inherited defects in NER genes result 
in the skin cancer-prone disease Xeroderma pigmentosum (Cleaver 1968).  In 
non-replicating cells NER factors sense UV-induced DNA damage and excise the 
lesion in a multi-step process. The remaining short single-stranded DNA (ssDNA) 
region serves as a template for repair synthesis, “gap” repair (Hoeijmakers 2001; 
Gillet & Schärer 2006). Lesions escaping NER gap repair stall replication forks 
and initiate checkpoint responses.  Some NER factors interact with the replisome 
and contribute to the early S phase checkpoint response (Bomgarden et al. 2006; 
Gilljam et al. 2012).  In post-replication repair lesions are managed largely 
through DNA-damage tolerance mechanisms (Sogo et al. 2002; Byun et al. 2005; 
Cortez 2005). Among the recent factors involved in this process is the hereditary 
breast cancer-associated gene product BRCA1, which function independently of 
NER to suppress mutations (Pathania et al. 2011).   
 
Several lines of evidence indicate that UV-induced damage is also limited 
by proteins of the DNA mismatch repair (MMR) pathway. MMR factors induce 
checkpoints, apoptosis, preserve genomic stability, and suppress cancer induced 
by UV irradiation (Nara et al. 2001; Meira et al. 2002; Yoshino et al. 2002; Seifert 
et al. 2008; Borgdorff et al. 2006).  The mechanism by which MMR functions in 
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response to UV irradiation could stem from its general role in genome 
surveillance and mismatch correction.  Canonical MMR begins with the 
recognition of replication errors where MSH2-MSH6 (MutSα) or MSH2-MSH3 
(MutSβ) assemble and recruit the heterodimer MLH1-PMS2 (MutLα) (Kunkel & 
Erie 2005). These complexes function in the repair of mismatched bases.  As 
such, loss of MMR confers a mutator phenotype and a predisposition to 
hereditary nonpolyposis colon cancer (HNPCC) (Jiricny 2006).   However, it is 
also well appreciated that MMR proteins respond to DNA damage from 
exogenous sources, such as to DNA alkylating agents, known to induce 
mismatches following DNA replication (Kaina et al. 2007).   In response to UV 
irradiation, MMR factors could have an alternative non-canonical role in UV 
lesion processing given that the MSH2-MSH6 complex directly binds UV lesions 
(Mu et al. 1997; Wang et al. 1999). Clarifying how MMR contributes to genomic 
stability in the UV response will be central to understanding the HNPCC variant, 
Muir-Torre syndrome that is characterized by skin cancers (Mathiak et al. 2002; 
Kruse et al. 1998; Suspiro et al. 1998).  
 
Both the MMR protein, MLH1 and BRCA1 bind directly to the DNA 
helicase FANCJ that hitherto has not been described as a factor in the UV 
response, but has essential functions in activating checkpoints following 
replication stress (Cantor et al. 2001; Peng et al. 2007; Gong et al. 2010; Cotta-
Ramusino et al. 2011; Xie et al. 2012).  FANCJ is mutated in hereditary breast 
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and ovarian cancer as well as in the rare cancer-prone syndrome Fanconi 
anemia (FA) (Cantor et al. 2001; Litman et al. 2005). Complementation studies 
using FANCJ deficient (FA-J) patient cells demonstrated that MLH1 binding is 
critical for FANCJ function in the repair of DNA interstrand crosslinks (ICLs) 
(Peng et al. 2007).  Here, we reveal that MLH1 binding to FANCJ is also 
essential for the response to UV-induced damage, in which FANCJ promotes an 
S phase checkpoint point and limits UV-induced mutations.  Because dual 
incision by NER also promotes FANCJ accumulation at sites of UV induced 
damage, and the NER endonuclease XPF was recently shown to be an FA gene 
similar to FANCJ, our analysis suggests that FA, MMR and NER pathways 
collaborate to process UV lesions in S phase cells to preserve the genome 
(Bogliolo et al. 2013; Kashiyama et al. 2013). 
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Results 
FANCJ accumulation at sites of UV induced damage is dependent on NER 
dual incision 
We examined the response of FANCJ to UV irradiation by assessing 
whether FANCJ accumulated at sites of UV-induced damage.  Following UV-
irradiation through 3 or 5 micron filters to generate sites of localized UV damage 
(LUDs) (Moné et al. 2001; Volker et al. 2001), we found that FANCJ co-localized 
with UV-induced 6-4 pyrimidine-pyrimidones (6-4 PPs), cyclobutane pyrimidine 
dimers (CPDs), and the NER endonuclease XPF in the breast cancer cell line, 
MCF7.   FANCJ localization to 6-4 PP- or XPF-positive LUDs peaked ~3 h after 
UV irradiation and diminished by ~12 h (Figure 2-1).   
 
To address the relationship of FANCJ to NER, we used XP cell lines and 
their functionally complemented counterparts.  We found that the accumulation of 
FANCJ at LUDs was reduced ~2- to 3-fold in NER-deficient XP-A, XP-F and XP-
G cells when compared to wild-type complemented cells (Figures 2-2, 2-3, 2-4). 
Contributing to FANCJ localization was XPF and XPG endonuclease activity as 
complementation with XPF or XPG nuclease-defective mutant species, XPFD676A 
or XPGE791A failed to restore robust FANCJ accumulation at LUDs between ~1-5h 
post UV-induced damage (Figures 2-3, 2-4) (Staresincic et al. 2009). Following 
global UV irradiation, FANCJ foci were also more prominent in XP-F cells 
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complemented with wild type XPF endonuclease (Figure 2-5). By contrast, 
FANCJ depletion did not affect the localization dynamics of NER factors (Figure 
2-6).  Collectively, these data indicate that NER incision events potentiate the 
accumulation of FANCJ to sites of UV-induced damage. 
 
NER promotes the accumulation of FANCJ at UV induced damage in S 
phase  
Next, we investigated whether NER contributed to FANCJ accumulation at 
LUDs in a specific cell cycle phase. Cells within S-phase and non-S phase can 
be easily distinguished after local UV irradiation by staining for 5-ethynyl-2’-
deoxyuridine (EdU) incorporation into genomic DNA (Limsirichaikul et al. 2009).  
In S-phase cells, EdU staining is bright and pan nuclear.  In non-S phase cells, 
EdU staining is restricted to sites of LUDs, representing sites of unscheduled 
DNA synthesis that occurs during gap repair in NER (Volker et al. 2001; 
Limsirichaikul et al. 2009; Sertic et al. 2011).  Following localized UV irradiation, 
cells were incubated in media with EdU for 3 h and immunostained with FANCJ 
antibodies. Consistent with a role for XPF in NER dependent gap filling, EdU 
positive LUDs in non-S phase cells were only present in XPFWT cells (Figure 2-7). 
FANCJ recruitment to LUDs was not significantly improved in non-S phase 
XPFWT cells, however it was significantly enhanced in S-phase XPFWT cells 
indicating that XPF potentiates FANCJ accumulation in cells undergoing DNA 
synthesis (Figure 2-7).  
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 FANCJ localization to sites of UV induced damage is MMR dependent 
FANCJ directly binds BRCA1, which functions in the response to UV 
irradiation selectively in S/G2 phase cells (Pathania et al. 2011; Cantor et al. 
2001). FANCJ also directly binds MLH1, which along with other MMR factors 
function in the response to UV irradiation and preserve genomic integrity (Peng 
et al. 2007; Young et al. 2003).  Because both BRCA1 and MLH1 contribute to 
FANCJ localization and function in the DNA damage response, we investigated 
whether BRCA1 or MLH1 interactions were required for FANCJ localization to 
LUDs. We analyzed FANCJ recruitment in FANCJ deficient FA-J patient cells 
complemented with empty vector, FANCJWT, the BRCA1-interaction defective 
mutant (FANCJS990A), or the MLH1-interaction defective mutant (FANCJK141/142A) 
(Peng et al. 2007; Yu et al. 2003).  While the FANCJ species expressed at 
similar levels, we found that FANCJK141/142A localization was dramatically reduced 
as compared to FANCJS990A, which localized to LUDs just as efficiently as 
FANCJWT (Figure 2-8). Importantly, FANCJ positive LUDs were not detected in 
FANCJ-null FA-J cells unless complemented with wild-type FANCJ confirming 
the specificity of our FANCJ antibody (Figure 2-8).   
 
Further validating that FANCJ localization to LUDs requires functional 
MMR, we found that as compared to a non-silencing control (NSC), FANCJ 
recruitment to LUDs was severely reduced in U2OS cells depleted of MLH1, 
42
MSH2, or MSH6 (Figures 2-9, 2-10). In contrast, XPC and ERCC1 recruitment to 
LUDs was not affected by MSH2 depletion (Figure 2-11), indicating that MMR is 
required for accumulation of FANCJ at LUDs, but not XPC or ERCC1. Likewise, 
MSH2 recruitment to LUDs was similar in vector and XPFWT complemented XP-F 
cells while as expected ERCC1 was only present in the XPFWT complemented 
XP-F cells suggesting that MMR and NER accumulation at LUDs is not inter-
dependent (Figure 2-11).  We also noted that the residual accumulation of 
FANCJ found at LUDs in XP-F cells was eliminated by depletion of MSH2 (Figure 
2-12), suggesting that NER and MMR operate in a parallel manner to support 
FANCJ localization.  In the XP-F cells, however MSH2 depletion did not perturb 
FANCJ nuclear or chromatin localization suggesting MMR and NER contribute to 
FANCJ localization to LUDs as opposed to nuclear import (Figure 2-13).  
 
We expected that both NER and MMR would also be present in S phase 
cells given that they contribute to the S phase localization of FANCJ.  However, 
NER proteins are best known for their UV repair function in non-S phase cells  
and from the literature it was not clear if MMR proteins had a cell cycle 
dependent localization to LUDs (Gillet & Schärer 2006). We used primary 
immortalized 48BR fibroblasts that have been used to characterize NER proteins 
in gap repair by means of EdU incorporation (Sertic et al. 2011).  While XPF was 
clearly present in non-S phase cells at sites of gap filling, as expected, we also 
detected XPF in nearly all LUDs in S phase cells, ~95% (Figure 2-14).  MLH1 
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and MSH2 were also present at LUDs with a similar percent in both non-S and S 
phase cells.  Instead, FANCJ was primarily at LUDs in S phase cells, ~86% and 
only in ~19% of non-S phase cells (Figure 2-14). Collectively, these studies show 
that MMR and NER proteins localize to LUDs in both non-S and S phase cells 
whereas FANCJ localizes primarily in S phase cells. 
 
FANCJ promotes the UV induced arrest of DNA synthesis and the induction 
of RPA phosphorylation  
UV irradiation activates checkpoint responses and inhibits DNA replication 
in S phase cells (Kaufmann & Cleaver 1981; Kaufmann 2010).  Given the role of 
FANCJ in checkpoint responses and the accumulation of FANCJ at LUDs during 
S-phase, we tested if FANCJ contributed to the UV-induced checkpoint response 
(Kumaraswamy & Shiekhattar 2007; Gong et al. 2010; Xie et al. 2012).  By 
pulsing cells with EdU, we found that FA-J cells expressing FANCJWT underwent 
a 10.5-fold reduction in S-phase cells when examined 16 h after UV irradiation. 
By comparison, FA-J cells expressing vector underwent a 2.0-fold reduction 
(Figure 2-15), indicating that FANCJ contributes to the arrest of DNA synthesis in 
response to global UV irradiation.  
 
The UV induced arrest of DNA synthesis is also associated with changes 
in phosphorylation of the single-stranded DNA-binding protein RPA (Carty et al. 
1994). Following UV-irradiation, the 32 kDa subunit of RPA is phosphorylated on 
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several serine residues in the N-terminal of the protein in a cell cycle dependent 
manner by DNA-PK and cyclin dependent kinases (Niu 1997; Zernik-kobak et al. 
1997). By examining phosphorylation of serines4/8 on RPA32 with a specific 
antibody, we found that in response to global UV irradiation FANCJ 
complementation was sufficient to enhance RPA serines4/8 phosphorylation in 
FA-J cells by fluorescent activated cell sorting (FACS) (Figure 2-16).  By FACS 
analysis basal phospho-S4/8 RPA32 was ~1-2% in both untreated vector and 
wild-type FANCJ complemented FA-J cells.  Following UV-irradiation, phospho-
S4/8 RPA32 was induced to ~22% in FANCJWT FA-J cells as compared to only 
~7% in vector FA-J cells (Figure 2-16).  Likewise, using phospho-S4/8 RPA32 
immunostaining in conjunction with EdU pulse, we uncovered that phospho- S4/8 
RPA32 staining was detected only in S phase cells (Figure 2-17).   Furthermore, 
we found that FA-J patient cells complemented with FANCJWT or the BRCA1-
interaction defective mutant (FANCJS990A) had significantly greater EdU positive 
S-phase cells with phospho-S4/8 RPA32 positive LUDs as compared to the FA-J 
cells complemented with empty vector or the MLH1-interaction defective mutant 
(FANCJK141/142A) (Figure 2-17).  This finding further suggested that FANCJ and 
the FANCJ-MLH1 interaction, but not the BRCA1-interaction contributes to 
checkpoint responses in S phase cells.  
 
Depletion experiments confirmed the role of FANCJ in promoting 
checkpoint responses to UV irradiation.  In FANCJ-depleted MCF7 cells, 
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phospho-S4/8 RPA32 as well as the soluble checkpoint factor phospho-317 
CHK1 was reduced compared to non-silencing control (NSC) while total CHK1 
and RPA levels were unchanged (Figure 2-18).  Co-immunostaining with 
phospho-S4/8 RPA32 and 6-4 PP antibody to visually mark UV induced LUDs 
also revealed that phospho-S4/8 RPA32 was significantly reduced in FANCJ 
depleted MCF7 cells as compared to NSC (Figure 2-19).  Interestingly, by 12h 
post-UV damage, a small, but significant persistence of UV induced 6-4 PP LUDs 
remained in FANCJ depleted cells (Figure 2-19).  FANCJ or MSH2 depletion also 
consistently enhanced the persistence of 6-4 PP positive LUDs in the male lung 
cancer cell line, A549 in which the formation of phospho-S4/8 RPA32-positive 
LUDs was also significantly reduced (Figure 2-20).  Furthermore, the 
combination of FANCJ and MSH2 depletion was not additive (Figure 2-20), 
suggesting that FANCJ and MSH2 function in a common pathway that is not cell 
type specific.  
 
Recently NER factors were shown to promote the S phase checkpoint 
response, including RPA phosphorylation in response to UV irradiation 
(Bomgarden et al. 2006; Auclair et al. 2008; Gilljam et al. 2012).  Given that the 
mechanism by which NER promotes the S phase checkpoint is unclear, we 
considered whether the NER-dependent accumulation of FANCJ at LUDs in S 
phase was required. As before, XP-F patient cells were segregated into non-S 
and S phase cells by labeling with EdU and phospho-S4/8 RPA32 staining was 
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detected only in S phase cells (Figure 2-21). We found that phospho-S4/8 
RPA32 induction was greatest in XP-F cells complemented with XPFWT (Figure 
2-21).  Strikingly, depletion of FANCJ or MSH2 profoundly reduced the phospho-
S4/8 RPA32 induction of XPFWT complemented XP-F cells (Figure 2-21).  
Notably, the residual phospho-S4/8 RPA32 positive LUDs found in vector 
complemented XP-F cells were also reduced by depletion of FANCJ or MSH2 
(Figure 2-21).  Thus, FANCJ promotes S phase checkpoint responses in not only 
cancer cell lines, but also in non-transformed fibroblasts.  Together, these data 
suggest that MSH2 and FANCJ contribute to NER-dependent and independent 
UV-induced phospho-S4/8 RPA32 induction at LUDs in S phase cells. In 
contrast, when either FANCJ or MSH2 were depleted, we found gap filling was 
proficient in the XP-F cells complemented with XPFWT (Figure 2-22).  Gap filling 
was also proficient in 48BR cells depleted of FANCJ, MLH1, or MSH2, but 
reduced in cells depleted of XPF (Figure 2-23).  Msh2 -/- and Msh2+/+ mouse 
embryonic fibroblasts also had similar levels of gap filling (Figure 2-23), 
suggesting that FANCJ and MMR factors are not required for NER-dependent 
gap filling.   
 
Collectively, our data indicate that FANCJ contributes to the UV induced 
arrest of DNA synthesis by potentiating checkpoint induction pathways.  While 
FANCJ does not contribute to NER-dependent gap repair, it influences the 
clearance of UV induced lesions in a common pathway with MSH2.    
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FANCJ suppresses UV-induced mutations 
Given that FANCJ is dispensable for survival after UV exposure, we 
sought to examine if FANCJ preserves the integrity of the genome, as has been 
found for MMR (Borgdorff et al. 2006; J Xie et al. 2010). Male A549 cells are 
useful for analyzing mutations at the endogenous hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) locus located on the X-chromosome (Chiu et 
al. 2006).  Similar to other cell lines examined, in A549 cells FANCJ localized to 
sites of UV induced damage as demonstrated by co-precipitation of FANCJ with 
CPD and modified PCNA following UV-induced damage (Figure 2-24).   
 
Using RNAi-mediated FANCJ silencing, we confirmed that FANCJ was not 
essential for survival following UV irradiation, but was essential for survival 
following exposure to the DNA cross-linking agent cisplatin (Figures 2-25, 2-26).  
As compared to NSC, we found that FANCJ depletion enhanced UV-induced 
HPRT inactivating mutations determined by clonal selection in 6-thioguanine 
(Chiu et al. 2006).  FANCJ depletion did not affect spontaneous HPRT mutations, 
but the frequency of inactivating HPRT mutations after 10J/m2 UV irradiation was 
enhanced ~10-fold in A549 cells (Figure 2-26).  Sequencing of clones arising 
from HPRT inactivation indicated no gross deletions or rearrangements as a 
consequence of FANCJ deficiency in response to global UV irradiation. Instead, 
HPRT inactivation was predominated by ~8-fold more C to T transitions in both 
the transcribed strand (TS) and non-transcribed strand (NTS) of HPRT in FANCJ 
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depleted cells (Figure 2-26, Table 2-1).  These findings suggest that FANCJ is 
involved in a specific process that suppresses the formation of point mutations in 
response to UV irradiation.  Further supporting that FANCJ suppresses 
inactivating mutations at the HPRT locus, FANCJWT-complementation in FANCJ 
deficient FA-J patient cells was sufficient to reduce survival in 6-thioguanine (6-
TG) after UV irradiation, indicating that it averted the occurrence of mutations 
(Figure 2-27). Furthermore, complementation with FANCJWT enhanced 
resistance to DNA cross-linking agent, mitomycin C (MMC), while in accordance 
with the results found in A549 cells, the resistance to UV irradiation was 
unchanged (Figure 2-27). Together, these results suggest that FANCJ, similar to 
MMR, contributes to the prevention of mutations in response to UV irradiation, 
without affecting long-term survival following this treatment (Nara et al. 2001; 
Meira et al. 2002; Yoshino et al. 2002; Seifert et al. 2008). Thus, we propose that 
in collaboration with NER, the MMR-FANCJ pathway is important for the 
response to UV irradiation in S phase to ensure checkpoint responses, genome 
stability and limit tumorigenesis (Figure 2-28). 
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indicated Abs. (B) Quantification of XP-A cells with FANCJ-
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tailed, unpaired t-test; *p ≤0.05, **p ≤0.01, ***p ≤0.005.  
 
51 
B XP-F cells 
%
 C
el
ls
 w
ith
 F
A
N
C
J 
(+
) L
U
D
   
**  * 
0 
10 
20 
30 
40 
50 
60 
70 
0.5 1 2 3 4 5(h) 
Vector 
XPFWT 
XPFD676A 
XP-F + vector XP-F + XPFWT XP-F + XPFD676A 
3(h) 
6-4PP  FANCJ FANCJ FANCJ 6-4PP  6-4PP  
4 
A 
2-3 FANCJ recruitment to sites of local UV-induced damage 
(LUDs) is dependent on XPF catalytic activity (A) XP-F cells 
complemented with empty vector, XPFWT, or XPFD676A were UV 
irradiated through 3 µm filters to generate LUDs and co-
immunostained with the indicated Abs. (B) Quantification of XP-F 
cells with FANCJ-positive LUDs.  
52 
B 
%
 C
el
ls
 w
ith
 F
A
N
C
J 
(+
) L
U
D
  XP-G cells 
* 
 ** 
0 
10 
20 
30 
40 
50 
60 
70 
0.5 1 2 3 4 5(h) 
Vector 
 XPGWT 
 XPGE791A 
A XP-G + XPGE791A XP-G + vector XP-G + XPGWT 
2(h) 
6-4PP  FANCJ FANCJ FANCJ 6-4PP  6-4PP  
4 
2-4 FANCJ recruitment to sites of local UV-induced damage 
(LUDs) is dependent on XPG catalytic activity (A) XP-G cells 
complemented with empty vector XPGWT, or XPGE791A were UV 
irradiated through 3 µm filters to generate LUDs and co-
immunostained with the indicated Abs. (B) Quantification of XP-
G cells with FANCJ-positive LUDs.  
53 
DAPI FANCJ 
XP-F 
+ vector 
XP-F 
+ XPFWT 
XP-F 
+ XPFD676A 
%
 C
el
ls
 w
ith
 ≥
 5
 F
A
N
C
J 
fo
ci
 (3
h)
  
0 
5 
10 
15 
20 
25 
30 
   
XP-F cells 
Vector XPFWT  XPFD676A 
B A 
2-5 FANCJ focal accumulation in response to global UV-
irradiation is dependent on XPF catalytic activity (A) XP-F 
cells complemented with empty vector, XPFWT, or XPFD676A were 
UV irradiated and co-immunostained with the indicated Abs. (B) 
Quantification of XP-F cells with FANCJ-positive foci.  
54 
0 
10 
20 
30 
40 
50 
60 
70 
0.5 1 3 5 12 
shNSC 
shFANCJ-1 
shFANCJ-2 
(h) 
A549 cells 
%
 C
el
ls
 w
ith
 X
PC
 (+
) L
U
D
  
0 
10 
20 
30 
40 
50 
60 
70 
0.5 1 3 5 12 (h) 
A B 
%
 C
el
ls
 w
ith
 E
R
C
C
1 
(+
) L
U
D
  
2-6 NER factors are recruited to sites of local UV-induced 
damage (LUDs) independently of FANCJ  (A) A549 cells 
containing unique shRNA vectors targeting FANCJ or NSC were 
UV irradiated through 5 µm filters , co-immunostained with the 
indicated Abs at several time points and quantified for cells with 
ERCC1 positive LUDS and (B) XPC positive LUDs.  
55 
B A 
0 
10 
20 
30 
40 
50 
Non-S S 
Vector 
XPF WT 
%
C
el
ls
 w
ith
 F
A
N
C
J 
(+
) L
U
D
 (3
h)
  
 ** Ed
U
/D
A
PI
 
FA
N
C
J 
XPFWT     Vector 
XP-F cells 
2-7 NER dependent FANCJ recruitment to sites of local UV-
induced damage (LUDs) occurs predominantly in S phase 
(A) XP-F cells complemented with empty vector or XPFWT were 
UV irradiated through 5 µm filters, incubated with EdU, and co-
immunostained with the indicated Abs. (B) Quantification of XP-F 
cells with FANCJ-positive LUDs.  
56 
FANCJ 
FA-J cells 
βACTIN  
B 
C 
%
 C
el
ls
 w
ith
 (+
) L
U
D
 (2
h)
  
0 
10 
20 
30 
40 
50 
60 
70 
80 
    
FANCJ 
6-4 PP 
     * 
 
FA-J cells  
Vector FANCJWT FANCJS990A 
6-
4 
PP
/D
A
PI
 
FA
N
C
J 
FANCJK141/142A 
 
FA-J cells  
A 
2-8 FANCJ recruitment to LUDs is dependent on MLH1 
interaction and independent of BRCA1 interaction.  (A) FA-J 
cells were complemented with empty vector, FANCJWT, 
FANCJS990A, or FANCJK141/142A and analyzed by immunoblot. (B) 
FA-J cells were UV irradiated through 5 µm filters, co-
immunostained with the indicated Abs, and quantified for FA-J 
cells with (C) FANCJ- and 6-4 PP-positive LUDs.  
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2-9 FANCJ recruitment to LUDs is dependent on mismatch 
repair factors MLH1 and MSH2 (A)  U2OS cells containing 
shRNA vectors targeting MLH1 or NSC were analyzed by 
immunoblot and (B) UV irradiated through micropore filters and 
(C) quantified for cells with FANCJ- or 6-4 PP-positive LUDs. (D) 
U2OS cells containing shRNA vectors targeting MSH2 or NSC 
were analyzed by immunoblot and (E) UV irradiated through 
micropore filters and (F) quantified for cells with FANCJ- or 6-4 
PP-positive LUDs.  
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2-10 FANCJ recruitment to LUDs is dependent on the 
mismatch repair factor MSH6 (A)  U2OS cells containing 
shRNA vectors targeting MSH6 or NSC were analyzed by 
immunoblot and (B) UV irradiated through micropore filters and  
quantified for cells with FANCJ- or 6-4 PP-positive LUDs. 
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2-11 MMR and NER factors are independently recruited to 
sites of local UV-induced damage (LUDs)  (A) U2OS cells 
containing shRNA vectors targeting MSH2 or NSC were UV 
irradiated through 5 µm filters and co-immunostained with XPC 
and ERCC1 abs. Representative images are shown 2 h after UV 
irradiation.  (B)  Quantification of cells with XPC- or ERCC1-
positive LUDs. (C) XP-F cells complemented with empty vector 
or XPFWT were UV irradiated through 5 µm filters and co-
immunostained with MSH2 and ERCC1 abs.  Representative 
images are shown 2 h after UV irradiation. (D) Quantification of 
XP-F cells with MSH2- or ERCC1-positive LUDs.  
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2-12 Residual FANCJ accumulation at LUDs in XP-F cells 
during S phase is eliminated by depletion of MSH2 (A) XP-F 
cells complemented with empty vector were stably depleted of 
MSH2 vs. NSC and analyzed by immunoblot. (B) Cells were UV 
irradiated through 5 µm filters, incubated with EdU, and co-
immunostained with the indicated Abs. (C) Quantification of XP-F 
cells with FANCJ-positive LUDs.  
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2-13 MSH2 depletion does not perturb FANCJ chromatin 
localization XP-F cells containing shRNA vectors targeting 
MSH2 or NSC were UV irradiated through micropore filters, pre-
extracted with 0.5% Triton-X in PBS prior to fixation, and co-
immunostained with the indicated Abs, a representative image is 
shown 2 hrs post UV irradiation.  
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2-14 FANCJ co-localizes with UV induced LUDs 
predominantly in S phase (A) 48BR cells were UV irradiated 
through 5 µm filters prior to incubation with 10uM EdU for 3 hrs 
and co-immunostained with the indicated Abs. (B) Quantification 
of co-localization of XPF, FANCJ, MLH1, or MSH2 with LUDs in 
non-S phase cells representing sites of gap filling and (C) 
quantification of co-localization of XPF, FANCJ, MLH1, or MSH2 
with LUDs in S-phase cells.  
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2-15 FANCJ contributes to the arrest of DNA synthesis in 
response to UV irradiation (A) FA-J cells complemented with 
empty vector or FANCJWT were left untreated and pulsed for 45 
minutes with 10 uM EdU or globally UV irradiated and pulsed for 
45 minutes with 10 uM EdU 16 h later.  Cells were processed for 
EdU incorporation and co-stained with DAPI. (B) Quantification 
of EdU incorporation/total number of DAPI (+) cells. ≥1000 DAPI 
cells were quantified for each experiment in triplicate.  
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2-16 FANCJ contributes to phosphorylation of RPA FA-J cells 
complemented with empty vector or FANCJWT were left untreated 
or UV-irradiated and analyzed by FACS sorting for pS4/8 RPA32 
positive cells, representative plots are shown.  
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2-17 FANCJ contributes to phosphorylation of RPA during S 
phase (A) FA-J cells complemented with empty vector or 
FANCJWT were UV irradiated through 5 µm filters, incubated with 
10uM EdU for 3 h, and co-immunostained with phospho-S4/8 
RPA32 Ab. (B) Quantification of cells with phospho-S4/8 RPA32 
positive LUDs and S-phase cells.  
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2-18 FANCJ contributes to the UV induced checkpoint. (A) 
Whole cell extracts of MCF7 cells containing shRNA vectors 
targeting FANCJ or NSC were analyzed by immunoblot and (B) 
were analyzed by immunoblot with the indicated Abs at the 
indicated time points after UV irradiation. The ratio of phospho-
protein/total protein by densitometry using Image J software is 
quantified.  
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2-19 FANCJ contributes to the UV induced checkpoint and 
elimination of UV induced lesions. (A) MCF7 cells containing 
shRNA vectors targeting FANCJ or NSC were UV irradiated 
through 5 µm filters to generate LUDs and co-immunostained 
with the indicated Abs at several time points.  (B) Quantification 
of cells with phospho-S4/8 RPA32-positive LUDs. (C) 
Quantification of 6-4 PP-positive LUDs.  
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2-20 FANCJ and MMR function in a common pathway for 
RPA phosphorylation and 6-4 Photoproduct elimination (A) 
A549 cells containing shRNA vectors targeting FANCJ or NSC 
were stably depleted of MSH2 versus a second NSC and 
analyzed for immunoblot or (B) UV irradiated through 5 µm filters 
to generate LUDs and co-immunostained with the indicated Abs 
at several time points and quantified for cells with phospho-
serine4/8 RPA32-positive LUDs and (C) 6-4 PP-positive LUDs.  
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2-21 FANCJ and MSH2 are required for RPA phosphorylation 
in S phase (A) XP-F cells complemented with empty vector or 
XPFWT were stably depleted of FANCJ, MSH2, or NSC using 
shRNA vectors and analyzed by immunoblot.  (B) Cells were UV 
irradiated through 5 µm filters , incubated with EdU, and co-
immunostained with the indicated Abs. (C) Quantification of 
phospho-S4/8 RPA32 positive LUDs in S phase cells expressing 
shNSC (D) shFANCJ and (E) shMSH2. 
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2-22 FANCJ and MSH2 are not required for NER dependent 
gap filling (A) XP-F cells complemented with empty vector or 
XPFWT were stably depleted of FANCJ, MSH2, or NSC using 
shRNA vectors and cells were UV irradiated through 5 µm filters , 
incubated with EdU, and co-immunostained. Quantification of 
NER dependent gap filling in non-S phase cells expressing 
shNSC (B) shFANCJ and (C) shMSH2.  
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2-23 FANCJ and MMR factors are not required for NER 
dependent gap filling (A) 48BR cells containing shRNA vectors 
targeting XPF, FANCJ-1, FANCJ-2, MLH1, MSH2 or NSC were 
UV irradiated through micropore filters prior to incubation with 
10uM EdU for 3 hrs and quantified for gap-filling in non-S cells. 
(B) MSH2 isogenic mouse embryonic fibroblasts were analyzed 
by immunoblot, treated as in A, and quantified for gap filling in 
non- S phase cells.  
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2-24 FANCJ precipitates with UV modified PCNA and CPD 
from chromatin extracts. A549 cells were left untreated or 
globally UV irradiated and collected in 150 nM NETN buffer and 
sonicated. The sonicated fraction was spun down and the \lysate 
was used for input or for CPD immuno-precipitation (IP).  IPs 
were then analyzed by immunoblot with the indicated Abs.  
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2-25 FANCJ deficient cells are sensitive to the DNA 
interstrand crosslinking agent cisplatin (A) A549 cells 
expressing shRNA vectors targeting FANCJ or NSC were left 
untreated or treated with Cisplatin and analyzed for colony 
survival. (B) Quantification of surviving colonies.  
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2-26 FANCJ suppresses UV-induced mutations. (A) A549 
cells expressing individual shRNA vectors targeting FANCJ or 
NSC were analyzed by immunoblot and (B) left untreated or 
globally UV irradiated and analyzed for colony survival.  (C) 
Quantification of surviving colonies. (D) Quantification of 6-
thioguanine (6-TG)-resistant HPRT mutant colonies from 
mutagenesis assay.  (E) Quantification of the distribution of 
HPRT-inactivating mutations in A549 cells expressing shRNA to 
NSC and (F) or shRNAs to FANCJ (combined).  
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#Clones 
Position (Strand) 
(NTS+; TS-)   (Sequence Change (5'->3') Exon Amino Acid 
shNSC 
2 97(-) CTTT(C>T)CAAA 2 Glu->Lys 
1 112(+) TATT(C>T)CTCA 2 Pro->Ser 
1 260(-) ATTT(C>T)TATT 3 Arg->Lys 
3 400(-) TCTT(C>T)CACA 5 Glu->Lys 
1 443(+) CTTT(C>T)CTTG 6 Ser->Phe 
1 374(+) ACTT(T>C)AACT 4 Leu->Ser 
1 297(+) ATTT(T>A)ATCA 3 Phe->Leu 
1 374(+) ACTT(T>A)AACT 4 Leu->Stop 
 shFANCJ 1+2 
5 112(+) TATT(C>T)CTCA 2 Pro->Ser 
4 145(+) ACGT(C>T)TTGC 3 Leu->Phe 
1 149(+) CTTG(C>T)TCGA 3 Ala->Val 
3 212(-) ATAG(C>T)CCCC 3 Gly->Asp 
1 227(+) TTTG(C>T)TGAC 3 Ala->Val 
9 260(-) ATTT(C>T)TATT 3 Arg->Lys 
7 272(-) GGAT(C>T)TATC 3 Arg->Lys 
3 275(+) AGAT(C>T)CATT 3 Ser->Phe 
2 280(+) CATT(C>T)CTAT 3 Pro->Ser 
1 281(+) ATTC(C>T)TATG 3 Pro->Leu 
3 364(+) TGAT(C>T)TCTC 4 Leu->Phe 
1 379(-) TTTC(C>T)AGTT 4 Gly->Arg 
2 380(-) CTTT(C>T)CAGT 4 Gly->Glu 
6 400(-) TCTT(C>T)CACA 5 Glu->Lys 
2 412(-) GTGT(C>T)AATT 6 Asp->Asn 
1 443(+) CTTT(C>T)CTTG 6 Ser->Phe 
7 500(-) GGTC(C>T)TTTT 7 Arg->Lys 
3 509(-) ACTT(C>T)GTGG 7 Arg->Gln 
5 544(-) ATTT(C>T)AAAT 8 Glu->Lys 
3 224(+) TTCT(T>C)TGCT 3 Phe->Ser 
2 296(+) GATT(T>C)TATC 3 Phe->Ser 
2 367(+) TCTC(T>C)CAAC 4 Ser->Pro 
3 437(+) ACTT(T>C)GCTT 6 Leu->Ser 
1 532(+) AGAC(T>C)TTGT 7 Phe->Leu 
3 263(-) ACTA(T>A)TTTC 3 Asn->Ile 
1 407(+) GATA(T>A)AATT 6 Ile->Lys 
1 409(-) TCAA(T>A)TATA 6 Ile->Phe 
1 543(+) GATT(T>A)GAAA 8 Phe->Leu 
1 280(+) CATT(C>G)CTAT 3 Pro->Ala 
1 443(+) CTTT(C>G)CTTG 6 Ser->Cys 
Table 2-1 List of UV-induced mutations at HPRT locus  
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2-27 FANCJ suppresses UV-induced mutations (A) FA-J cells 
expressing empty vector control or FANCJWT were UV irradiated 
and analyzed for survival in 6-TG relative to untreated cells (B) 
Empty vector control- or FANCJWT-complemented FA-J cells 
were analyzed for relative survival after mitomycin C treatment. 
Cells were stained with crystal violet, solubilized, and 
absorbance was measured at 590nm. The relative absorbance of 
treated/untreated was quantified as relative survival. (C) FA-J 
cells were treated as in D, except analyzed for relative survival 
after UV irradiation. 
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2-28 FANCJ functions in response to UV irradiation Model of 
FANCJ function in response to UV-irradiation.  NER and MMR 
factors are recruited to sites of local UV induced damage in non-
S phase cells where NER, but not MMR, is required for gap 
filling.   In S-phase cells, both NER and MMR factors contribute 
to the accumulation of FANCJ.  MMR through MLH1 binding 
localizes FANCJ to sites of UV induced damage. NER incision 
enhances the accumulation of FANCJ at the lesion site. 
Collectively, these events ensure a robust checkpoint response 
to limit the replication of damaged DNA, induction of mutations, 
and cancer.  
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2-29 Mutations in FANCJ and MMR loci occur in melanoma 
genomes FANCJ protein coding mutations were identified from 
sequenced melanoma genomes in cBioPortal and the Catalogue 
of Somatic Mutations in Cancer (CoSMiC) databases. Mutations 
are located throughout the FANCJ sequence as indicated. Two 
specific amino acids were previously identified, in hereditary 
breast cancer (blue) and in Fanconi Anemia (green). Mutations 
found in the iron-sulfur domain (red).  Sites where FANCJ 
interacts with MLH1 (K141/K142) and BRCA1 (S990) are 
indicated.  
I II  Ia III IV V VI  NLS 
P47L 
V187A 
G190E 
G304E 
H317Y 
A464G 
S624L 
S644L 
L679F 
Q685fs 
R831_splice I983S 
S956L 
E1039fs 
P1101L 
P1238S 
P1246L 
1 1249 AA 
  BRCA1 
 
 MLH1 
 
Fe-S 
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Table 2-2 List of Mutations in FANCJ and MMR loci from 
melanoma genomes protein coding mutations were identified 
from sequenced melanoma genomes in cBioPortal and the 
Catalogue of Somatic Mutations in Cancer (CoSMiC) databases. 
FANCJ 
P47L Missense 
V187A Missense 
G190E Missense 
G304E Missense 
H317Y Missense 
A464G Missense 
S624L Missense 
S644L Missense 
L679F Missense 
Q685* Nonsense 
R831_splice Splice Site 
I983S Missense 
S956L Missense 
E1039fs Frameshift 
P1101L Missense 
P1238S Missense 
P1246L Missense 
P47L Missense 
V187A Missense 
G190E Missense 
MLH1 
R217C Missense 
H315Y Missense 
T347I Missense 
S368L Missense 
L507* Nonsense 
L521fs Frameshift 
p.? (c.1732-1G>A) Intronic  
MSH2 
Q395* Nonsense 
P476S Missense 
L478F Missense (Squamous) 
R680* Nonsense 
C822F  Missense 
MSH6 
K155R Missense 
R240*  Nonsense 
G306K Missense 
A457V Missense 
P623L  Missense 
S677I Missense 
T757I Missense 
M868I Missense 
Q939*  Nonsense 
T1008I  Missense 
T1219I  Missense 
PMS2 
S769F Missense 
K178R Missense 
S769F Missense 
R151C Missense 
S128L Missense 
H634Y Missense 
H552R Missense 
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2-30 Ectopic expression of catalytic inactive FANCJK52R 
disrupts clearance of UV induced lesions in U2OS cells (A) 
U2OS cells were transfected with pCDNA3 constructs containing 
vector, FANCJWT, or FANCJK52R and analyzed by immunoblot 
wit the indicated Abs. (B) Cells were UV irradiated through 5 um 
filters to generate LUDs and co-immunostained with the 
indicated Abs 16h post treatment and (C) quantified for cells with 
phospho-serine4/8 RPA32-positive LUDs and 6-4 PP-positive 
LUDs.  
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2-31. FANCJ expression promotes UV induced GFP-polη 
foci formation in U2OS cells (A) U2OS cells were transfected 
with GFP-polη and left untreated or globally UV irradiated and 
analyzed on a fluorescent microscope. (B) Cells were co-
transfected with GFP-polη and siRNA reagents targeting 
luciferase control, FANCJ, or RAD18 and analyzed by 
immunoblot with the indicated Abs. (C) Cells were left untreated 
or globally UV irradiated quantified for cells with >5 GFP-polη 
foci.  
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Conclusions 
Here, we show that both NER and MMR proteins promote the localization 
of the FANCJ DNA helicase to sites of UV-induced lesions to ensure a robust S 
phase checkpoint response.  MMR proteins initially recruit FANCJ and its further 
accumulation requires dual incision by the NER endonucleases XPF and XPG 
(Figures 2-2, 2-3, 2-4).  Although FANCJ-deficiency does not cause UV-induced 
sensitivity, this analysis revealed an important role for FANCJ in promoting an S 
phase checkpoint response, lesion repair, and suppressing UV-induced 
mutations (Figures 2-15, 2-16, 2-17, 2-18, 2-19). Consistent with FANCJ and 
MMR functioning in a common pathway, we found that FANCJ or MMR 
deficiency alone or in combination generated similar defects (Figure 2-20).  
Correspondingly, the direct interaction between MLH1 and FANCJ is essential for 
both FANCJ localization and function at sites of UV-induced damage, whereas 
the BRCA1 interaction is not required (Figure 2-8).  Similar to NER, MMR 
proteins localize to LUDs in both non-S and S phase cells whereas FANCJ is 
predominantly found at sites of UV-damage in S phase cells (Figure 2-14).   
Together, this work demonstrates that distinct pathways merge in S phase cells 
to ensure a robust UV-induced DNA damage response.   
 
These findings are important in light of the fact that defects in MMR have 
been associated with skin cancers found in the HNPCC variant Muir-Torre 
syndrome (Kruse et al. 1998; Suspiro et al. 1998; Mathiak et al. 2002). 
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Furthermore, we searched for both FANCJ and MMR mutations within 
sequenced melanoma genomes using cBioPortal and the Catalogue of Somatic 
Mutations in Cancer (CoSMiC) database (Cerami et al. 2012; Gao et al. 2013; 
Forbes et al. 2011).  We identified mutations in FANCJ, MSH2, MSH6, MLH1, 
and PMS2 (Figure 2-29, Table 2-2).  The majority of FANCJ mutations target the 
helicase domain including domains important for enzyme function, such as the 
Fe-S domain and helicase boxes III, IV, and V (Figure 2-29).  In addition, some of 
the mutations have been detected previously. The FANCJP47 residue was 
targeted in breast cancer and was shown to be ATPase and helicase inactive in 
vitro (Cantor et al. 2004).  The splice mutant FANCJR831 is an allele in FA and 
eliminates conserved helicase boxes required for enzyme function (Cantor et al. 
2004; Gupta et al. 2005; Cantor & Guillemette 2011). To determine if loss of 
FANCJ ATPase/helicase/translocase activity disrupts the UV response, we 
attempted to express the catalytic inactive FANCJK52R mutant in FA-J cells. 
Because FANCJ deficient FA-J cells are defective in the UV response and the 
FANCJK52R mutant has weak expression compared to FANCJWT, it was unclear if 
the mutant was defective in complementing FA-J cells or mediating the UV 
response.  Thus, we overexpressed the FANCJK52R mutant in U2OS cells.  Here, 
we found significant defects in lesion clearance at 16 h following UV damage, but 
no significant affect on RPA phosphorylation at this time point (Figure 2-30). 
Thus, loss of FANCJ expression could disrupt checkpoint activation, whereas 
expression of an enzyme inactive mutant could dominantly disrupt repair. 
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Further supporting that multiple pathways contribute to high fidelity repair 
after UV irradiation, similar to skin tumors from XP patients, MMR deficient and 
FANCJ-deficient cells display an elevated frequency of UV-induced C>T point 
mutations (Table 2-1) (Dumaz et al. 1993; Borgdorff et al. 2006). Similar to 
FANCJ deficiency, MMR deficiency also has modest affects on UV sensitivity 
despite reduced checkpoint and apoptotic responses (Yoshino et al. 2002; van 
Oosten et al. 2005). Thus, we propose that FANCJ intersects MMR and NER 
dependent repair pathways to promote efficient checkpoint activation, lesion 
clearance, and suppress UV-induced mutations (Figure 2-28).  Conceivably, in 
the absence of FANCJ and its checkpoint function error-prone polymerases 
induce mutations at sites of UV induced lesions.  Indeed, the high-fidelity TLS 
polymerase, polη has reduced foci formation in response to global UV irradiation 
in FANCJ deficient cells (Figure 2-31).  
 
The NER factor XPA contributes to the S phase checkpoint following UV-
induced irradiation.  However, not all NER factors are required suggesting that 
this checkpoint function is distinct from NER repair in G1 phase (Gillet & Schärer 
2006).  These findings further suggest that XPF promotes RPA phosphorylation 
in S phase cells (Figure 2-21). Interestingly, XPF is the FA gene, FANCQ
(Bogliolo et al. 2013; Kashiyama et al. 2013).  Given that XPF promotes FANCJ 
accumulation in S phase cells, this data also suggests that FANCJ functions 
downstream of this FA factor to promote RPA phosphorylation throughout S 
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phase. NER dependent incision may provide a better substrate or change the 
DNA structure, enabling distribution of FANCJ at the lesion site (Figure 2-28).
Here, FANCJ could facilitate repair of lesions ahead of the replication fork 
through checkpoint induction and the arrest of DNA synthesis to limit mutation 
induction.  Conceivably this function is shared by FANCJ partners, such as 
Bloom’s syndrome helicase (BLM), or the FA pathway, explaining its link to the 
UV response and checkpoints that limit genomic instability (Suhasini et al. 2011; 
Kelsall et al. 2012; Singh et al. 2009; Nalepa et al. 2013).  It has long been 
proposed that ATR-BLM and FA pathway interactions maintain the genome by 
restoring productive replication following replication stress (Davies et al. 2004; 
Olson et al. 2006; Sobeck et al. 2006). 
 
The two-step mobilization of FANCJ to UV-induced lesions, localization by 
MMR and further accumulation after NER dependent post-incision could ensure 
pathway coordination.  Indeed, the combined loss of NER and MMR enhances 
UV-induced mutagenesis (Nara et al. 2001). While MMR and NER proteins have 
been shown to have overlapping substrates, it remains to be determined whether 
they bind the same or a distinct type of UV lesion (Zhao et al. 2009). FANCJ 
loading by MLH1 is reminiscent of the requirement of the bacterial MutL, 
homologous to the MutLα complex, for loading helicase II (UvrD) onto DNA 
(Mechanic et al. 2000). Helicase II functions with DNA polymerase I to release 
oligonucleotide fragments containing UV photoproducts (Caron et al. 1985). In 
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contrast to Helicase II, our data do not support a role for FANCJ or MMR in gap 
repair.  However, these findings do not exclude the possibility that MMR and 
FANCJ contribute to the fidelity of NER-dependent gap filling.  Alternatively, 
loading of FANCJ by MMR factors could unwind and disrupt secondary DNA 
structures that impede NER processing. Indeed, MMR factors bind secondary 
structures such as G-4 quadruplex DNA that FANCJ unwinds (Larson et al. 2005; 
Wu et al. 2008).  Our group also previously reported that FANCJ depends on 
MLH1 for localization to sites of DNA interstrand crosslinks (Suhasini et al. 2013).  
 
Collectively, the data presented in this manuscript provide a framework for 
understanding the contributions of distinct DNA repair pathways to the DNA 
damage response to UV irradiation in human cells.  The identification of a novel 
function for MMR in localizing FANCJ to sites of UV induced damage could be 
useful for several reasons.  First, a functional assay examining FANCJ or MMR 
localization to LUDs could help in the discrimination between missense and 
pathogenic MMR variants, especially those identified by melanoma genome 
sequencing studies.  Loss of FANCJ localization and function could be also 
uniquely disrupted by MMR gene mutations as found in tumors in which 
canonical MMR is intact.  Second, the MMR-FANCJ pathway could represent a 
unique tumor suppression pathway that provides opportunities for selective 
therapy in effected tumors.  In melanoma, loss of FANCJ function or expression 
could be a consequence of not only FANCJ mutations (Table 2-2), but also MMR 
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mutations.  Indeed, ~5.7 % of tumors are affected by FANCJ mutations, which 
did not co-segregate with MMR gene mutations (Cerami et al. 2012; Gao et al. 
2013). Associated skin tumors may be selectively sensitive to ICL-inducing 
agents, which is a hallmark of FA-J patient cells.  In light of the recent finding that 
XPF is the FA gene, FANCQ, it will be important to determine if the FA pathway 
has a more fundamental role in the response to UV irradiation and/or in reducing 
the emergence of disease (Bogliolo et al. 2013; Kashiyama et al. 2013).  
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 Materials and Methods 
 
Cell Culture 
A549, MCF7, and U2OS cells were cultured in DMEM (Gibco, Life Technologies) 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.  FA-
J, 48BR, MEFs, GM04429 XP-A, XP2YO XP-F, and XPCS1RO XP-G cells and 
their respective complements were cultured in DMEM supplemented with 15% 
fetal bovine serum and 1% penicillin/streptomycin.  Patient cell lines XP2YO XP-
F, XPCS1RO XP-G and their respective complements were generated by Dr. 
Orlando Schärer and MSH2-/- or +/+ MEFs were a generous gift of Janet 
Stavnezer.  
 
DNA constructs 
FA-J cells were infected with pOZ retroviral vectors 32 expressing FANCJWT, 
FANCJK141/142A, FANCJS990A, or empty vector as described earlier 23, 24.  Stable 
cell lines were generated by sorting with anti-IL-2 magnetic beads (Dyna Beads). 
The pCDNA-3myc-6xhis vectors were generated with a QuickChange site-
directed mutagenesis kit (Stratagene) using published primers for FANCJK52R 23.  
GFP-polη was expressed in U2OS cells as described in (Kannouche et al., 2001, 
Watanabe et al., 2004, Xie et al., 2010).  
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 RNA Interference 
The packaging cell line 293TL was used to produce lentiviral particles containing 
pGIPZ or pLKO.1 vectors and 293TD cells were used to produce retroviral 
particles containing pStuffer vector. Cells were transfected with 1:1:2 ug of DNA 
packaging versus insert using Effectene® transfection reagent (Qiagen) 48 h prior 
to harvesting retroviral or lentiviral supernatants. Supernatants were filtered and 
added to recipient cell lines with 1 ug/ml polybrene. Cells infected with shRNA 
vectors were selected with either puromycin (pGIPZ, pLKO.1) or hygromycin 
(pStuffer). For shRNA-mediated silencing the mature antisense was used for 
pLKO.1 shNSC 5’CCGCAGGTATGCACGCGT3’, shMLH1 
5’AATACAGAGAAAGAAGAACAC3’, shMSH2 
5’AAACTGAGAGAGATTGCCAGG3’, 
shXPF5’AAATCACTGATACTCTTGCGC3’, shFANCJ 
5’TATGGATGCCTGTTTCTTAGCT3’, for pGIPZ shNSC 
5’ATCTCGCTTGGGCGAGAGTAAG3’, shMSH2-1 
5’ATTACTTCAGCTTTTAGCT3’, shMSH2-2 
5’GCATGTAATAGAGTGTGCTAA3’, shMSH6-1 
TTCAACTCGTATTCTTCTGGC, and shMSH6-2 
TTTCAACTCGTATTCTTCTGG.  The pStuffer vectors were a generous gift of Dr 
Junjie Chen. The pStuffer shRNA targeting luciferase was 
5’GUGCGCUGCUGGUGCCAAC3’, shFANCJ-1 5’GUACAGUACCCCACCUUAU 
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3’, and shFANCJ-2 5’GAUUUCCAGAUCCACAAUU3’.  RNAi mediated depletion 
of Luciferase, FANCJ, or RAD18 using siRNA reagents was performed as 
described previously (Xie et al., 2010) 
 
Local UV irradiation and Immunofluorescence 
Local UV irradiation was performed as described 33 using a 254 nm UV lamp 
(UVP inc., Upland, CA) with a dose of 100 J/m2 though 3 or 5 um Isopore 
polycarbonate membrane filters (Millipore). Cells were fixed for 10 min with either 
ice cold methanol or 3% paraformaldehyde/2% sucrose in phosphate buffered 
saline (PBS), permeabilized for 5 min with 0.5% Triton X-100, and treated with 
0.08M NaOH for 2 min. only prior using 6-4 PP or CPD Abs. Coverslips were 
rinsed 3x in 1xPBS prior to each step.  For immunostaining using combined 
cocktails of primary or secondary antibody staining, cells were incubated for 40 
min. each in a humid chamber, face down on a 100uL meniscus of antibody 
cocktails diluted in 3%BSA in PBS.  Primary Abs used were anti-FANCJ (1:500 
Sigma, Lot #051M4759, #014K4843), anti-pS4/S8 RPA32 (1:500 Bethyl), anti-
MLH1 (1:200 BD Bioscience), anti-MSH2 (1:200 Calbiochem), anti-XPF (1:200 
Neomarkers), anti-ERCC1 (1:500 Santa Cruz), anti-XPC (1:500 Abcam), anti-6-4 
PP, and anti-CPD (both 1:1000 CosmoBio). Secondary Abs used include 
Rhodamine Red-X conjugated AffiniPure Goat anti-rabbit or anti-mouse IgG and 
fluorescein (FITC)-conjugated AffiniPure Goat anti-rabbit IgG (Jackson Immuno-
research Laboratories Inc). Coverslips were mounted on slides using 
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Vectashield® mounting media with DAPI (Vecta laboratories, Inc) and analyzed 
on a fluorescence microscope (Leica DM 5500B) with a Qimaging Retiga 2000R 
Fast 1394 camera. For each experimental time point ≥400 DAPI-positive cells 
(≥1200 in triplicate) were analyzed using Q-Capture Pro line intensity profile 
software with the intensity gated at ≥0.1 for positive LUDs for 6-4 PP or CPD 
staining. The accumulation of a protein at an LUD was considered positive if its’ 
intensity was 10-fold greater than the line drawn over the rest of the nucleus.  
Positive LUDs were scored separately for each variable, either protein or UV 
induced lesion, and then divided by the number of cells analyzed using DAPI 
stain. 
 
Mutation Frequency Assays 
The HPRT assay was performed in A549 cells as described 34 with the following 
modifications. After culturing cells for 1 week in media containing hypoxanthine, 
aminopterin, and thymidine (HAT selection) to eliminate background HPRT 
mutations, cells were stably depleted of FANCJ with two unique shRNA targets 
versus a non-silencing control and selected with hygromycin.  UV-induced HPRT 
mutants were obtained by seeding 6 plates at a confluence of 1x106 cells/10 cm 
dish 24 h prior to either mock treatment, 5, or 10 J/m2 UV irradiation in a 254 nm 
SpectrolinkerTM XL-1500 (Dot Scientific, Inc). Post-treatment cells were allowed 
to recover to 6x106 cells or with mock cells 6 population doublings and 6x106 
cells were seeded at a confluence of 1x106/10 cm dish in media containing 24 
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uM 6-Thioguanine (6-TG) to select for HPRT-inactivated colonies. At the same 
time 200 cells were also seeded in 6-TG-free media to determine colony-forming 
efficiency.  The frequency of inactivating mutations at the HPRT locus was 
calculated as the [(# of total 6-TG resistant colonies) / (6x106 cells seeded)] x the 
colony-forming efficiency. HPRT inactivation frequency represents the mean of 
three independent experiments.  Individual colonies were picked and grown until 
enough cells were obtained for RNA isolation using TRIzol® Reagent (Life 
Technologies) according to the manufacturer’s protocol. The HPRT gene was 
subjected to RT-PCR using SuperScript® (Invitrogen) followed by sequencing 
using overlapping primers HPRT1 5′CTTCCTCCTCCTGAGCAGTC3′; HPRT2–
5′AAGCAGATGGC-CACAGAACT3′; HPRT3–5′CCTGGCGTCGTGATTAGTG3′; 
HPRT4–5′TTTAC-TGGCGATGTCAATAGGA3′; HPRT5–
5′GACCAGTCAACAGGGGACAT3′; and HPRT6 
5′ATGTCCCCTGTTGACTGGTC3′.  Patient-derived FA-J cells were 
complemented with empty vector or FANCJWT and treated as described with 
A549 cells. As FA-J cells do not make colonies, the % increase in 10uM 6-TG 
survival was calculated as the % of UV-irradiated cells surviving 6-TG minus the 
% of untreated cells surviving 6-TG. The % increase in 6-TG survival represents 
the mean of three independent experiments. 
 
EdU Labeling 
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EdU incorporation was performed as described previously (Limsirichaikul et al 
2009), except cells were seeded on coverslips and left untreated or UV-irradiated 
through 5 micron filters prior to 3 h incubation in 10uM EdU diluted in serum free 
media. When using global UV-irradiation, cells were left untreated and pulsed 45 
min in 10 uM EdU or UV-irradiated and pulsed 16 h later for 45 min with 10 uM 
EdU.   Cells were processed by Click-iT® EdU imaging kit (Invitrogen) using the 
manufacturer’s instructions immediately followed by the above 
immunofluorescence protocol.   
 
Western Blot  
Cells were harvested and lysed in 150 mM NETN lysis buffer (20mM Tris (pH 
8.0), 150 mM NaCl, 1mM EDTA, 0.5% NP-40, 1mM phenylmethylsulfonyl 
fluoride, and 1x protease inhibitor cocktail) for 30 minutes on ice.  Cell extracts 
were clarified by centrifugation at 14,000 rpm, protein was quantified by Bradford 
assay, and lysates were boiled in SDS loading buffer.  Chromatin extracts were 
prepared as described 35. For CPD immune-precipitation cells were lysed in 150 
nM NETN buffer and sonicated.  The  lysate was quantified by Bradford assay 
and then pre-cleared with Protein A beads and immuno-precipitated overnight 
with CPD Abs. Proteins were separated by SDS-PAGE on 4-12% bis Tris or 3-
8% Tris Acetate gels (Novex, Life Technologies) and electrotransferred onto 
nitrocellulose membranes.  Membranes were blocked in 5% milk diluted in PBS.  
Antibodies used for Western blot analysis included anti-FANCJ (1:1000 Sigma, 
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1:1000 E67 (previously described 36, anti-Bactin (1:5000 Sigma), anti-MLH1 
(1:500 BD Bioscience), anti-MSH2 (1:500 Calbiochem), anti-MSH2 (mouse 
specific, Santa Cruz ), anti-XPF (1:1000 Neomarkers), anti-ERCC1 (1:500 Santa 
Cruz), anti-XPC (1:1000 Abcam), anti-CHK1 (1:500 Bethyl), anti-p317 CHK1 
(1:500 Bethyl), anti-RPA32 (1:500 Bethyl), and anti-pS4/S8 RPA32 (1:500 
Bethyl).  Membranes were washed and incubated with horseradish peroxidase-
linked secondary antibodies (Amersham 1:5000), and detected by 
chemiluminescence (Ambersham).  The ratio of phospho-protein to total protein 
was measured and quantified using Image J software. 
 
FACS Analysis 
FA-J cells cultured to ~ 80% confluency were left untreated or globally irradiated 
with 5 J/m2 before collecting and fixing in 70% ethanol 4 h post UV irradiation.  
For antibody labeling, cells were rinsed with1x PBS, pearmabilized with 0.5% 
Triton-X 100 in PBS 20 minutes at room temperature, and then washed with 1% 
BSA/0.25% Tween-20 in PBS (PBS-TB) before re-suspending 1 h in PBS-TB 
with pS4/S8 RPA 32 antibody (1:250 Bethyl).  Cells were then collected and 
washed 2x in PBS-TB prior to 1 h incubation in PBS-TB containing FITC-
conjugated AffiniPure Goat Anti-Rabbit IgG (1:200 Jackson Immuno-research 
Laboratories, Inc.).   After washing with PBS, cells were re-suspended in RNAse 
A solution (100 µg/mL in PBS) for 20 min at room temperature and again washed 
with PBS prior to FACS analysis. Cells were labeled with propidium iodide prior 
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to analysis on a FACSCaliber flow cytometer (Becton-Dickinson) performed at 
the University of Massachusetts Medical School flow cytometry core facility using 
Cellquest software.  The fluorescence intensity of pS4/S8 RPA 32 positive cells 
was gated as FITC-positive cell populations compared to no antibody control.   
 
 
 
Statistics 
All quantitative data were collected from experiments performed in triplicate, and 
expressed as mean ± s.d.  Differences between experimental groups were 
calculated using a two-tailed, unpaired student t-test using Excel Microsoft or 
Graphpad.  Where shown, asterisks denote significance *p ≤0.05, **p ≤0.01, ***p 
≤0.005.         
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CHAPTER III: 
CISPLATIN RESISTANCE SCREEN IN BRCA2 MUTANT CELLS 
Preface 
 The work in this chapter stems from a collaboration with Sharon Cantor 
and Michael Green’s laboratories.  Michael’s former graduate student Ryan Serra 
was essential for helping me launch the shRNA screen.  Ryan taught me the 
importance of optimization prior to launching the screen and helped me organize 
the validation scheme after recovering the candidates.  His guidance and 
constructive criticism was ongoing throughout this project and has been a 
tremendous help.  Amy Virbasius aided in the preparation of virus for candidate 
validation. Although I proceeded with the validation process of the candidates, 
several undergraduates and high school students assisted in the counting of 
colonies so that it could be performed in a blind format. 
 A former rotation student, Janelle Hayes, assisted with depletion of 
additional NuRD complex members and also helped to raise virus used to 
deplete CHD4 in other various experiments.  Panagiotis Konstantinopoulos from 
Dana Farber compiled the mutations from BRCA2 mutant ovarian tumors and 
performed the Kaplan Meier plot analysis to examine progression free survival 
and overall survival in tumors with different levels of CHD4 mRNA expression.   
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Abstract 
Therapies taking advantage of underlying defects in DNA repair are 
effective on cancer cells harboring mutations in the hereditary breast cancer 
genes, BRCA1 or BRCA2. As with traditional chemotherapies however, 
resistance develops. One mechanism includes reversion mutations in BRCA1 or 
BRCA2 that restore functional proteins and RAD51-based homologous 
recombination. More perplexing is the development of resistance without 
reversion mutations. Here, I find, in a genome-wide shRNA screen, that depletion 
of the chromatin-remodeling factor CHD4 confers cisplatin resistance in BRCA2-
mutant cells. Rescue by CHD4 depletion does not improve RAD51 foci formation 
as compared to rescue by BRCA2 reversion mutation.  However rescue similarly 
depends on BRCA2 suggesting that CHD4 depletion creates a gain-of-function 
for the N-terminal truncated BRCA2 protein. Consistent with CHD4 modulating 
therapeutic response, low CHD4 expression correlates with cisplatin resistance 
in BRCA2-mutant cell clones and poor patient response/survival in BRCA2-
mutant ovarian tumors.  
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Introduction 
 
Fanconi anemia (FA) and hereditary breast and ovarian cancer derive 
from common underlying gene defects that compromise DNA repair by 
homologous recombination (HR).  Thus, FA patient cells and BRCA-associated 
tumors are sensitive to DNA damaging agents that require homologous 
recombination (HR) for repair processing.  Loss of HR in BRCA1 and BRCA2-
mutant cancer cells also elicits synthetic lethality with PARP1 inhibitors (PARPi). 
As such, cisplatin and PARPi alone or in combination are actively being tested on 
a diverse set of tumors with suspected BRCA or HR associated pathway 
mutations (Rouleau et al. 2010; Ang et al. 2013).    
 
The efficacy of these therapies is limited, however by the development of 
resistance.  One mechanism underlying resistance in BRCA cancers is re-
established DNA repair.  In particular, HR is restored in both BRCA1 and BRCA2 
cancer cells through genetic rewiring events that re-instate functional gene 
products (Sakai et al. 2008; Swisher et al. 2008; Edwards et al. 2008; Sakai et al. 
2009). Alternatively, in BRCA1 mutant cells loss of the DNA repair protein 53BP1 
can restore DNA end resection and reinstate HR (Cao et al. 2009; Bunting et al. 
2010; Bouwman et al. 2010).  More importantly, increased 53BP1 expression 
levels correlate with improved progression free survival and overall survival in 
triple negative breast cancer patients (Bouwman et al. 2010).  In BRCA2 mutant 
cells, 53BP1 depletion is not sufficient to restore HR as BRCA2 is thought to 
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function downstream of DNA end resection (Bouwman et al. 2010). 
 
Interestingly, BRCA2 reversion mutations and genetic studies have 
uncovered essential domains required for HR. BRCA2 has 8 BRC repeats that 
are important for binding and loading the recombinase RAD51 onto resected 
DNA ends (Jensen 2013).  Surprisingly, only two BRC repeats are required for 
HR as long as the BRCA2 C-terminal DNA binding domain and the RAD51-DNA 
filament binding domains are also intact (Siaud et al. 2011).  BRCA2 mutant 
cancer cells and cells from Fanconi Anemia FA-D1 patients are defective for 
repair by HR, correspondingly, these BRCA2 mutations are predicted to truncate 
the protein (Howlett et al. 2002; Sakai et al. 2009).  Whereas promoter 
methylation and loss of BRCA1 expression occurs in triple negative breast 
cancer, this is not the case in BRCA2 mutant cancers (Collins et al. 1997; Matros 
et al. 2005).  Additionally, BRCA2 nullizygous mice result in embryonic lethality, 
whereas truncated forms of BRCA2 are sufficient for survival (Ludwig et al. 1997; 
Connor et al. 1997).  Taken together, these findings suggest that the N-terminal 
BRCA2 region could have HR independent functions required for cell viability.   
 
An interesting and perplexing finding is that BRCA2 mutant cells can 
develop resistance without reversion mutations or signs of restored HR.  BRCA2 
mutant cancer cell clones that are resistant to either cisplatin or PARP inhibition 
have been described (Sakai et al. 2008; Sakai et al. 2009; Norquist et al. 2011).  
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Moreover, chemoresistance in BRCA2 mutant cancers occurs without BRCA2 
reversion mutations in about half of ovarian tumors (Norquist et al. 2011). Thus, 
in BRCA2 mutant cancer cells, the absence of RAD51 foci does not accurately 
predict therapy response and the means by which tumors become resistant to 
therapy remains to be determined.    
 
In an attempt to uncover how BRCA2 mutant cancer cells gain resistance 
to therapy independently of genetic reversion I performed a genome-wide RNA 
interference screen in BRCA2 mutant ovarian cancer cells to identify genes 
required for cellular sensitivity to cisplatin.  The most robust candidate identified 
from my screen was the chromodomain helicase, CHD4, a member of the 
chromatin remodeling complex NuRD (Lai & Wade 2011).  CHD4 depletion in 
several BRCA2 mutant cell lines conferred resistance to cisplatin.  More 
importantly, examination of previously described BRCA2 mutant cell lines that 
were defective for HR and resistant to cisplatin for unknown reasons revealed 
that these clones have lost expression of CHD4 (Sakai et al. 2009).  Given that 
de novo loss of CHD4 could propel resistance to cisplatin in a BRCA2 mutant 
background in cell culture, we further examined if CHD4 expression levels could 
predict patient response in BRCA2 mutant ovarian tumors in the clinic.  
Astoundingly, low CHD4 expression levels significantly correlated with poor 
progression free survival and reduced overall survival in BRCA2-mutant ovarian 
tumors. 
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Results 
Genome wide screen identifies CHD4 as a modulator of cisplatin response 
in BRCA2 mutant cells 
To identify genetic determinants of cisplatin resistance in BRCA2 mutant 
cells, we employed a survival-based, loss of function RNAi screen. The screen 
was performed in PEO1 cells that originate from a high-grade serous ovarian 
tumor that lacks wild-type BRCA2, but carries an allele with a c.617delT 
frameshift mutation (Sakai et al. 2009). In contrast with the wild-type 3,418-
residue protein, the mutant allele encodes a truncated BRCA2 protein of 2,002 
amino acids that lacks the C-terminus and 4 BRC repeats (Figure 3-1).  
Consequently, the mutant protein fails to efficiently promote RAD51-based HR 
and PEO1 cells are sensitive to cisplatin (Figure 3-1). Similar to other BRCA 
mutant cell lines, cisplatin resistance in PEO1 cells can develop through 
unknown mechanisms or by the acquisition of reversion mutations that restore 
BRCA2 sequences critical for HR (Sakai et al. 2009). The cisplatin resistant 
PEO1 derived clone C4-2 expresses a revertant, full length protein that migrates 
slower and more similar to the wild-type BRCA2 protein (390 kDa) as compared 
to the parental truncated protein (224 kDa) (Figure 3-1).  As expected the 
functional BRCA2 restores robust RAD51 foci that are absent in parental PEO1 
cells despite cisplatin-induced DNA damage detected by γH2A.X foci (Figure 3-
1). Reinstated BRCA2 enhances resistance to cisplatin, as well as DNA double 
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strand break-inducing agents, such as zeocin (Figure 3-1). 
 For the genome-wide shRNA screen, cisplatin sensitive PEO1 cells were 
infected with viral pools containing the pGIPZ library.  Cells containing shRNA 
vectors were selected with puromycin, cisplatin treated and analyzed for colony 
formation (see Methods, Figure 3-2). The most pronounced increase in colony 
formation after cisplatin was observed with depletion of the chromodomain 
helicase, CHD4 a member of the nucleosome remodeling and deacetylase 
(NuRD) complex (Tong et al. 1998; Wade et al. 1998; Zhang et al. 1998).  Four 
shRNAs directed against CHD4 showed this effect, making off-target effects 
unlikely (Figure 3-3). Depletion of a distinct NuRD-complex protein, MBD2, in 
PEO1 cells reduced cellular fitness and enhanced cisplatin sensitivity (Figure 3-
4).  This finding suggests that CHD4 depletion and not loss of the NuRD 
remodeling complex rescues PEO1 cells.  Moreover, given that CHD4 depletion 
increased cisplatin resistance in two additional BRCA2 mutant cell lines, Fanconi 
anemia (FA) cell line, FA-D1 and in the pancreatic cancer cell line, CAPAN-1, 
these findings are not specific to a distinct cell line (Figure 3-5).   
Analysis of cell cycle profiles in response to cisplatin 
 We next examined cell cycle analysis in response to cisplatin in PEO1 
cells depleted of CHD4 verses a non-silencing control (NSC) and compared this 
C4-2 cells expressing a NSC (Figure 3-6).  Cell cycle analysis revealed that 
CHD4 depleted PEO1 cells more closely resembled the profile of BRCA2 
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proficient cells.  Specifically, while the majority of cells were all arrested in G2 
phase within 48 hours after cisplatin treatment, only the BRCA2 restored C4-2 
cells and CHD4 depleted PEO1 cells were able to recover 60 hours after the 
insult and proceed into the G1 phase.  At this dose of cisplatin, PEO1 cells 
containing the NSC remain stuck in G2 phase or develop sub-G1 content 
suggesting the accumulation of apoptotic events 120 hours after the insult.   
Conversely, the cell cycle profiles of BRCA2 restored C4-2 cells and CHD4 
depleted PEO1 cells are identical to the profiles of their untreated counterparts 
by 120 hours after cisplatin treatment indicating that their cell cycle is fully 
recovered (Figure 3-6).   
CHD4 depletion in BRCA2 mutant PEO1 cells does not restore HR repair 
The BRCA2 N-terminal mutant in PEO1 cells is defective for HR due to 
missing functional domains. However, given the cisplatin resistance phenotype 
associated with CHD4 depletion in PEO1 cells, we considered that these domain 
requirements could be circumvented by CHD4 depletion.  CHD4 depletion could 
instead propel BRCA2 reversion mutations and restore HR.  Thus, we addressed 
if CHD4 depletion in PEO1 cells restored RAD51 foci. As expected, we observed 
cisplatin-induced RAD51 foci co-incident with γH2A.X in the BRCA2 revertant 
C4-2 cells, but not in the parental PEO1 cells that express CHD4 (Figure 3-7). 
These RAD51 foci did not measurably improve in CHD4 depleted PEO1 cells 
although γH2A.X foci were clearly induced following cisplatin (Figure 3-7). 
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Moreover, examination of chromatin bound RAD51 in unperturbed and cisplatin 
treated PEO1 cells also suggested that CHD4 depletion did not enhance, but 
rather slightly reduced RAD51 localization to the nucleus (Figure 3-8).  
Furthermore, CHD4 depletion did not alter the expression or migration of the 
BRCA2-mutant species suggesting that the mutant species did not undergo a 
genetic reversion to restore the full length protein (Figure 3-8). Notably, CHD4 
expression and chromatin localization was not dependent on the BRCA2 C-
terminal domain given the similar chromatin association of CHD4 in PEO1 and 
C4-2 cells (Figure 3-8). Collectively, these findings suggest that CHD4 depletion 
in PEO1 cells confers cisplatin resistance without restoration of BRCA2 function 
in HR.    
Toxicities associated with CHD4 depletion are ameliorated in BRCA2 
mutant cells 
Enhanced cisplatin resistance by CHD4 depletion was counterintuitive 
given reports that CHD4 depletion causes sensitivity to DNA damaging agents 
(Luo et al. 2000; Pegoraro et al. 2009; Smeenk et al. 2010; Sims & Wade 2011; 
Polo et al. 2010; Larsen et al. 2010; Urquhart et al. 2011). Thus, we examined 
CHD4 depletion in the BRCA2 revertant C4-2 cells following exposure to distinct 
DNA damaging agents. In support of a role in DNA repair, we found that CHD4 
depletion in C4-2 cells enhanced sensitivity not only to cisplatin, but also to 
zeocin and the PARPi, Olaparib  (Figures 3-9, 3-10). In contrast, CHD4 depletion 
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in PEO1 cells enhanced resistance to each of these agents, albeit not to the level 
obtained in C4-2 cells with restored BRCA2 function (Figures 3-3, 3-10).  
Consistent with other reports, even without DNA damage, CHD4 depletion 
reduced plating efficiency (Figure 3-11) and induced γH2A.X (Figure 3-12) 
(Smeenk et al. 2010). However, while this effect was detected in C4-2 and U2OS 
cells, it was not detected in BRCA2 mutant PEO1 or FA-D1 cells (Figures 3-11, 
3-12).  
CIsplatin resistance mediated by CHD4 depletion is unique to BRCA2 
mutant cells 
We next sought to examine if CHD4 depletion uniquely rescued other HR 
defective cells. To test this idea, we analyzed the effect of CHD4 depletion in 
BRCA1 mutant breast cancer cell lines, HCC1937 and SUM1315MO2.  CHD4 
depletion as compared to control profoundly reduced proliferation and changed 
the morphology of cells such that too few cells were available for sensitivity 
assays (Figure 3-13). Correspondingly, immunofluorescence experiments 
revealed that CHD4 depletion enhanced γH2A.X foci formation (Figure 3-14). We 
also examined CHD4 depletion in other HR defective cell lines including FANCJ-
deficient (FA-J cells), FANCD2-deficient (PD20 cells), or XPF-deficient (XP-F 
cells).  While colony-forming efficiency was not overtly affected, CHD4 depletion 
did not enhance cisplatin resistance as found in BRCA2-mutant cells (Figure 3-
15).  
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CHD4 depleted PEO1 cells are uniquely sensitive to the histone 
deacetylase inhibitor Trichostatin A 
Next, we analyzed if CHD4 depletion generated cross-resistance to other 
DNA damaging agents in BRCA2 mutant cells. However, CHD4 depletion in 
PEO1 cells did not enhance resistance to 6-thioguanine (6-TG) or the 
bifunctional alkylator melphalan (Figure 3-16). Because CHD4 functions in the 
NuRD complex with histone deacetylaces, we also examined the effects of the 
histone deacetylase inhibitor, Trichostatin A (TSA) (Tong et al. 1998; Wade et al. 
1998; Zhang et al. 1998; Lai & Wade 2011).  Interestingly, CHD4 depletion in 
PEO1 cells, but not C4-2 cells, enhanced sensitivity to TSA (Figure 3-16). These 
results suggest that reduced CHD4 expression in BRCA2 mutant cells could 
bestow an altered chromatin state that could be targeted and effectively treated 
with histone deacetylase inhibitors. 
CHD4 depletion does not promote cisplatin resistance in BRCA2 deficient 
cells 
To further investigate the effect of CHD4 depletion in cells defective for 
BRCA2 function, we used RNAi to deplete BRCA2 alone or in combination with 
CHD4. As expected, BRCA2 depletion, similar to CHD4 depletion alone, induced 
γH2A.X and apoptosis as measured by caspase3 cleavage in C4-2 (Figure 3-17) 
and U20S cells (Figure 3-18).  Notably, these outcomes were similar in CHD4 
and BRCA2 co-depleted cells (Figures 3-17, 3-18). Furthermore, the cisplatin 
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sensitivity due to BRCA2 depletion was not alleviated by CHD4 co-depletion in 
either C4-2 or U2OS cells (Figures 3-17, 3-18). Together these findings suggest 
that CHD4 depletion does not rescue BRCA2-deficient cells.  
To test the possibility that rescue requires the N-terminal mutant BRCA2 
species present in BRCA2 mutant PEO1 cells (Figure 3-1), we again analyzed 
the effects of CHD4 and CHD4/BRCA2 co-depletion in PEO1 cells.  We found 
that BRCA2 RNAi substantially reduced the expression of the N-terminal BRCA2-
mutant product (Figure 3-19). Suggesting functional consequences for loss of the 
N-terminal BRCA2 mutant, γH2A.X expression was enhanced upon BRCA2 
depletion (Figure 3-19). To a lesser degree CHD4 and BRCA2 co-depletion also 
induced γH2A.X expression that was not detected in PEO1 cells with CHD4 
depletion alone (Figure 3-19). The cisplatin resistance obtained by CHD4 
depletion in PEO1 cells was also suppressed by BRCA2 co-depletion (Figure 3-
19).  Collectively, these data argue that the N-terminal mutant BRCA2 species 
contributes to suppressing γH2A.X induction and partially mediates cisplatin 
resistance in CHD4 depleted PEO1 cells.  
Derived cisplatin resistant ovarian cancer cell clones correspond with de 
novo loss of CHD4 expression 
Evidence suggests that N-terminal BRCA2 peptides that retain BRC 
repeats while defective in HR have partial function that promotes viability (Ludwig 
et al. 1997). PEO1 cells, similar to CAPAN-1 and FA-D1 cells, retain BRC 
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repeats (Howlett et al. 2002; Sakai et al. 2008; Sakai et al. 2009).  Given that 
BRCA2 mutant cells typically retain some form of truncated BRCA2, we sought to 
determine if CHD4 loss had clinical relevance. To investigate if derived cisplatin 
resistance results from de novo CHD4 loss, we analyzed CHD4 expression in a 
series of previously derived PEO1 cisplatin resistant clones lacking BRCA2 
reversion mutations and Rad51 focal induction (Figures 3-20, 3-21) (Sakai et al. 
2009).  As compared to the parental PEO1, or BRCA2 revertant clone C4-2, 
resistant clones, C4-4, C4-11, and C4-13 had reduced CHD4 protein expression 
levels (Figure 3-22). Interestingly, ectopic expression of GFP tagged CHD4 in the 
cisplatin resistant clone C4-4 was sufficient to restore sensitivity to cisplatin 
(Figure 3-23).  Moreover, similar to CHD4 depleted PEO1 cells (Figure 3-16), we 
found that cisplatin resistant clones with low CHD4 expression were also 
sensitive to the HDAC inhibitor TSA as compared to parental PEO1 and revertant 
C4-2 cells (Figure 3-24). 
 CHD4 expression predicts patient response to therapy in BRCA2 mutant 
ovarian tumors 
In light of our findings, we hypothesized that CHD4 expression levels 
could predict response to cisplatin based therapy specifically in BRCA2 mutant 
tumors.  Thus, CHD4 mRNA expression was examined in 312 spontaneous 
serous ovarian tumors for which overall survival (OS) was documented and 262 
ovarian tumors for which progression free survival (PFS) was documented using 
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database analysis.  Median CHD4 expression was used as a threshold to classify 
tumors as CHD4 over-expressed (above median) or CHD4 under-expressed 
(below median) and PFS and OS while assessed in patients.  In spontaneous 
tumors, CHD4 expression levels displayed no significant correlation with PFS or 
OS (Figure 3-25). Correlation between CHD4 expression and PFS in 30 BRCA1 
mutant tumors or OS in 36 BRCA1 mutant tumors was also not significantly 
predictive of response (Figure 3-26).  Compilation of BRCA2 mutant tumors 
revealed that the majority of tumors contain frameshift mutations or premature 
stop codons predicted to truncate the protein (Table 3-1).  Strikingly, analysis of 
CHD4 expression in the BRCA2 mutant tumors revealed that CHD4 over-
expression (above median) correlated with significantly improved PFS and 
improved OS in tumors from 32 patients (Figure 3-27).  These results suggest 
that CHD4 mRNA expression levels could serve as a valuable predictor of 
response to chemotherapy in patient tumors carrying a BRCA2 mutation. 
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3-1 PEO1 cells express nuclear truncated BRCA2 and are 
sensitive to DNA damaging agents compared to BRCA2 
revertant C4-2 cells (A) Cartoon showing BRCA2 mutant PEO1 
and BRCA2 revertant C4-2 cells (B) Cells were left untreated or 
cisplatin treated and nuclear extracts were analyzed by 
immunoblot with the indicated Abs. (C) PEO1 and C4-2 cells 
were left untreated or Cisplatin treated and analyzed for colony 
survival. (D) PEO1 and C4-2 cells were treated as in C, except 
with Zeocin. (E) PEO1 and C4-2 cells were treated as in B and 
co-immunostained with the indicated Abs.  
Figures 
111 
Lentiviral Infection of shRNA Pools 
(MOI 0.2 PEO1 cells) 
Puromycin Selection 
Cisplatin Treatment  
(~99% Death with  
Non-Silencing Control) 
Expand, Isolate Genomic DNA, PCR 
Amplify and Sequence to Identify 
Candidates 
Validation of Cisplatin Resistance 
 (PEO1 and FA-D1 cells) 
24 (h) 
1 week 
      
3-2 An RNA interference screen to identify mediators of 
cisplatin resistance in BRCA2 mutant cells Schematic of viral 
infection with shRNA pools and screening conditions. 
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3-3 An RNA interference screen identifies CHD4 as a 
mediator of cisplatin resistance in BRCA2 mutant cells (A) 
PEO1 cells containing two unique pGIPZ shRNA vectors 
targeting CHD4 or non-silencing control (NSC) were analyzed by 
immunoblot and (B) were left untreated or Cisplatin treated and 
analyzed for colony survival. (C) PEO1 cells containing two 
unique pLKO.1 shRNA vectors targeting CHD4 or non-silencing 
control (NSC) were analyzed by immunoblot and (D) were left 
untreated or Cisplatin treated and analyzed for colony survival. 
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3-4 Depletion of the nucleosome remodeling (NuRD) 
complex member MDB2 does not mediates cisplatin 
resistance (A) PEO1 cells containing pLKO.1 shRNA vectors 
targeting NSC, CHD4, or two unique shRNA vectors targeting 
MBD2 were analyzed by immunoblot.  (B) Cells were plated at 
low density and analyzed for colony forming efficiency. (C) Cells 
were left untreated or treated with cisplatin and quantified for 
colony survival. 
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3-6 Cell cycle profiles of BRCA2 restored C4-2 cells and 
BRCA2 mutant PEO1 cells depleted of CHD4 verses control 
in response to cisplatin C4-2  cells expressing an shRNA 
directed against NSC or PEO1 cells expressing shRNAs directed 
against NSC or CHD4 were left untreated or Cisplatin treated for 
24 h.  Cells were collected at several time points, propidium 
iodine stained, and analyzed for cell cycle. 
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3-7 CHD4 depletion in PEO1 cells does not restore RAD51 
foci formation (A) C4-2 and PEO1 cells containing pLKO.1 NSC 
vector or two unique shRNA vectors targeting CHD4 were 
analyzed by immunoblot with the indicated Abs. (B) Cells were 
left untreated or treated with 2 µM Cisplatin for 16h and co-
immunostained with the indicated Abs. A representative image of 
Cisplatin treated cells is shown. (C) quantification of % cells with 
≥5 γH2AX foci/cell or  (D) % cells with ≥5 RAD51 foci/cell.  
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3-8 CHD4 depletion in PEO1 cells does not restore full 
length BRCA2 PEO1 and C4-2  cells expressing shRNAs 
directed against NSC or CHD4 were left untreated or Cisplatin 
treated and nuclear extracts were analyzed with the indicated 
Abs. 
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3-9 CHD4 depletion causes cisplatin sensitivity in BRCA2 
proficient cells (A) BRCA2 revertant C4-2 cells containing two 
unique pGIPZ shRNA vectors targeting CHD4 or non-silencing 
control (NSC) were analyzed by immunoblot and (B) were left 
untreated or Cisplatin treated and analyzed for colony survival.  
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3-10 CHD4 depleted BRCA2 proficient cells are sensitive to 
DNA damage while BRCA2 mutant PEO1 cells are partially 
resistant (A) C4-2 cells containing pLKO.1 shRNA vectors 
targeting NSC or two unique vectors targeting CHD4 were plated 
at low density, left untreated or treated with the PARP inhibitor 
Olaparib, or (B) Zeocin, and quantified for colony survival.  (C) 
PEO1 cells containing pLKO.1 shRNA vectors targeting NSC or 
two unique vectors targeting CHD4 were plated at low density, 
left untreated or treated with the PARP inhibitor Olaparib, or (D) 
Zeocin, and quantified for colony survival.  
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3-11 CHD4 depletion is toxic in BRCA2 proficient cells, yet 
uniquely tolerated in BRCA2 mutant cells (A) BRCA2 
proficient C4-2 (top) and U2OS cells (bottom) containing pGIPZ 
shRNA vectors targeting CHD4 or non-silencing control (NSC) 
were seeded at low density and analyzed for colony forming 
efficiency after 7 days by fixation and Giemsa staining. (B) 
BRCA2 mutant PEO1 (top) and FA-D1 cells (bottom) were 
seeded at low density and analyzed for colony forming efficiency 
after 7 days by fixation and Giemsa staining.  
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3-12 CHD4 depletion is toxic in BRCA2 proficient cells, yet 
uniquely tolerated in BRCA2 mutant cells (A) BRCA2 
proficient C4-2 cells containing pLKO.1 shRNA vectors targeting 
CHD4 or NSC were immunostained with the indicated Abs and  
quantified for % cells with ≥5 H2AX foci (B) BRCA2 mutant 
PEO1 cells were treated as in A and quantified for % cells with 
≥5 H2AX foci. 
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3-13 CHD4 depletion mediates toxicity in BRCA1 mutant 
cells (A) BRCA1 mutant SUM1315MO2 cells containing pLKO.1 
shRNA vectors targeting CHD4 or NSC were analyzed by 
immunoblot and (B) representative bright field images are shown 
4 days after puromycin selection. (C) BRCA1 mutant HCC1937 
cells containing pLKO.1 shRNA vectors targeting CHD4 or NSC 
were analyzed by immunoblot and (D) representative bright field 
images are shown 4 days after puromycin selection. 
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3-14 CHD4 depletion mediates toxicity in BRCA1 mutant 
cells (A)  BRCA1 mutant HCC1937 cells containing pLKO.1 
shRNA vectors targeting CHD4 or NSC were immunostained 
with the indicated Abs and (B) quantified for % cells with ≥5 
H2AX foci.   
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3-15 CHD4 depletion does not mediate cisplatin resistance 
in other DNA repair deficient cells (A) FA-J cells containing 
pLKO.1 shRNA vectors targeting CHD4 or NSC were analyzed 
by immunoblot and (B) left untreated or cisplatin treated and 
quantified for colony survival. (C) XP-F cells were treated as in A 
and (D) quantified as in B. (E) PD20 cells were treated as in A 
and (F) quantified as in B.  
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3-16 CHD4 depleted PEO1 cells are sensitive to the HDAC 
inhibitor Trichostain A (TSA).   (A) PEO1 cells containing 
pLKO.1 shRNA vectors targeting NSC or CHD4 were plated at 
low density, left untreated or treated with 6-Thioguanine (6-TG) 
or (B) Melphalan and analyzed for colony survival. (C) PEO1 
cells or (D) C4-2 cells containing pLKO.1 shRNA vectors 
targeting NSC or two unique vectors targeting CHD4 were plated 
at low density, left untreated or treated with Trichostain A and 
quantified for colony survival.   
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3-17 Co-depletion of CHD4 and BRCA2 in BRCA2 proficient 
C4-2 cells does not mediate cisplatin resistance (A) C4-2 
cells were infected with pLKO.1 lentivrial vectors targeting NSC, 
CHD4, and BRCA2 or co-infected with vectors targeting CHD4 
and BRCA2 and analyzed by immunoblot with the indicated Abs.  
(B) Cells were left untreated or treated with Cisplatin and 
analyzed for colony survival.  
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3-18 Co-depletion of CHD4 and BRCA2 in BRCA2 proficient 
U2OS cells does not mediate cisplatin resistance (A) U2OS 
cells were infected with pLKO.1 lentivrial vectors targeting NSC, 
CHD4, and BRCA2 or co-infected with vectors targeting CHD4 
and BRCA2 and analyzed by immunoblot with the indicated Abs.  
(B) Cells were left untreated or treated with Cisplatin and 
analyzed for colony survival.  
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3-19 Cisplatin resistance mediated by CHD4 depletion in 
PEO1 cells requires expression of truncated BRCA2 (A) 
PEO1 cells were infected with pLKO.1 lentivrial vectors targeting 
NSC, CHD4, and BRCA2 or co-infected with vectors targeting 
CHD4 and BRCA2 and analyzed by immunoblot with the 
indicated Abs.  (B) Cells were left untreated or treated with 
Cisplatin and analyzed for colony survival.  
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3-20 Cisplatin resistant clones retain truncated BRCA2 and 
gain resistance by an unknown mechanism (A) Nuclear 
extracts of BRCA2 revertant C4-2 cells, BRCA2 mutant PEO1 
cells, and derived Cisplatin resistant clones C4-4, C4-11, and 
C4-13 were analyzed by immunoblot with the indicated Abs. and 
(B) left untreated or treated with cisplatin and analyzed for colony 
survival. 
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3-21 Cisplatin resistant clones do not restore RAD51 foci 
formation (A) BRCA2 mutant PEO1 cells, BRCA2 revertant 
C4-2 cells, and derived Cisplatin resistant clones C4-4, C4-11, 
and C4-13 were left untreated or treated with cisplatin and 
immunostained with the indicated Abs 16 hrs after treatment.  
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3-22 Cisplatin resistant clones have reduced CHD4 protein 
expression BRCA2 mutant PEO1 cells, BRCA2 revertant C4-2 
cells, and derived cisplatin resistant clones C4-4, C4-11, and 
C4-13 were analyzed by immunoblot with the indicated Abs.  
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3-23 Ectopic expression of GFP-CHD4 restores sensitivity to 
C4-4 cells  (A) PEO1, C4-2, and derived cisplatin resistant C4-4 
cells were mock or GFP-CHD4 transfected and analyzed by 
immunoblot 36 hrs post transfection with the indicated Abs. (B) 
Cells were left untreated or treated with cisplatin and analyzed 
for colony survival. The relative increase in cisplatin sensitivity of 
mock transfected/GFP-CHD4 transfected cells is quantified. 
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3-24 Cisplatin resistant clones are uniquely sensitive to 
Trichostain A (TSA) BRCA2 revertant C4-2 cells, BRCA2 
mutant PEO1 cells, and derived Cisplatin resistant clones C4-4, 
C4-11, and C4-13 were left untreated or treated with Trichostain 
A (TSA) and analyzed for colony survival. 
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3-25 Progression Free Survival (PFS) and Overall Survival 
(OS) does not correlate with CHD4 mRNA expression levels 
in sporadic ovarian cancers CHD4 mRNA association with 
Progression free survival (PFS)  (p=0.313) and Overall survival 
(OS) (p=0.641) in all serous ovarian tumors.  
136 
Su
rv
iv
al
 fr
ac
tio
n 
Su
rv
iv
al
 fr
ac
tio
n 
time time 
 BRCA1-mutant  BRCA1-mutant 
3-26 Progression Free Survival (PFS) and Overall Survival 
(OS) is not improved in BRCA1 mutant ovarian tumors with 
increased CHD4 mRNA expression  CHD4 mRNA association 
with PFS  (p=0.715) and OS (p=0.916) in BRCA1-mutant tumors. 
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3-27 Progression Free Survival (PFS) and Overall Survival 
(OS) is improved in BRCA2 mutant ovarian tumors with 
increased CHD4 mRNA expression CHD4 mRNA association 
with PFS (p=0.006) and OS (p=0.065) in BRCA2-mutant tumors.  
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AA change Mutation type 
 D1737fs  FS del 
 E1857fs  FS del 
 E342fs  FS del 
 K1406fs  FS del 
 L1491fs  FS del 
 L2696fs  FS del 
 L3277fs  FS del 
 Q1782fs  FS del 
 R1704fs  FS del 
 S1982fs  FS del 
 S1982fs  FS del 
 S1982fs  FS del 
 S1982fs  FS del 
 S1982fs  FS del 
 T219fs  FS del 
 T256fs  FS del 
 T2607fs  FS del 
 T3085fs  FS del 
 V1229fs  FS del 
 Y1710fs  FS del 
 G602fs  FS ins 
 E1143D  Missense 
 K1638E  Missense 
 T1354M  Missense 
 C711*  Nonsense 
 E294*  Nonsense 
 K3326*  Nonsense 
 K3326*  Nonsense 
 K3326*  Nonsense 
 R2394*  Nonsense 
 R2520*  Nonsense 
 S1882*  Nonsense 
 E2878_splice  Splice 
 V211_splice  Splice 
Table 3-1 BRCA2 mutations in ovarian tumors from patients 
used for Kaplan-Meier estimation 
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3-28 Model depicting how resistance to cisplatin occurs in 
BRCA2 mutant cells.  Upon cycles of treatment with cisplatin 
therapy resistant cells can emerge upon loss of CHD4 
expression or genetic reversion of BRCA2 to restore full length 
protein. 
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3-29 Partial validation of candidates identified in the shRNA 
screen (A) Candidates identified in the shRNA screen were 
depleted in PEO1 cells verses a non-silencing control (NSC) and 
examined for resistance to cisplatin at several concentrations, 
the 0.5 µM concentration is shown. (B) FA-D1 cells were treated 
as in A, except the 1.0 µM concentration is shown.  
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DNA Metabolism 
AHNAK  
CHD4 
NAP1L2  
PMS2L2  
POLK  
PRMT5  
PRMT7  
REV3L 
RNF20  
WDHD1  
 
 
RNA metabolism 
DDX1 
DDX18 
DQX1 
SFPQ 
 
Signal transduction   
ARHGEF17 
GPR64  
GREB1  
HTR3A  
NR4A2  
NUAK2  
PLCL1  
PPP2CB  
PTGES  
RASSF9    
SPA17  
TGFBR1  
TNFRSF1A 
  
Cell cycle regulation 
ALMS1 
MKI67 
PPP1CC 
USP44 
 
 
 
 
 
 
 
 
 
 
 
 
Transcription 
ASXL2  
ELL  
ETV3  
ETV3L  
MXD1  
PIAS1  
ZBTB38  
ZNF24  
ZNF280C  
ZNF560  
ZNF673  
 
Translational 
regulation 
CPEB1 
EIF4B 
EIF4H 
 
Intracellular protein 
transport 
BICD1 
HSPA5 
SLC15A4 
SLC7A11 
SLC04A1 
SYTL5 
 
Vesicle trafficking 
ARCN10L 
TPD52 
 
Cell motility/ 
adhesion 
ANKRD62 
COL28A1 
CPNE3 
MUC16 
PDLIM5 
SCIN 
 
 
 
 
 
 
 
 
 
 
 
Cell metabolism 
ALDH2  
 ALG6   
ATP11B  
 CDO1  
 CYP8B1  
 CRLS1  
DGKG  
DNAJA4  
 FECH  
  FMO9P  
 FUT9  
  GPX8  
 HECTD1   
HSD17B12  
MAT1A    
PSMC1   
SUMF1  
 TMLHE  
 UBE2G2  
 VDBP 
 
Channels 
KCNH1 
KCNH6 
KCNJ5 
 
 
Immunity 
IL2RB 
LY6G6E 
TLR5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unknown 
ARMCX5  
C1orf212  
C9orf23  
C10orf81  
C20orf194  
C21orf129 
CXorf23 
CCDC136  
COMMD10  
CTDSPL  
EFCAB2  
FAM26E  
KIAA0195  
KIAA0355  
KIAA0494  
LRFN2  
LRRC10B  
LRRC8B  
MYO15B 
NCRNA00294  
NOL4  
SHCBP1L  
SHISA9  
TMEM35  
TTC38  
UBE2D4  
WDR52  
WDSUB1  
Table 3-2 List of candidates identified in the cisplatin 
resistance shRNA screen in BRCA2 mutant PEO1 cells 
based on gene ontology. 
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 Revertant 
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C4-2 
 
PEO1 
   Nuclear Extracts 
 IP:BRCA2 N-term Ab 
3-30 Truncated BRCA2 can interact with RAD51 in a 
cisplatin inducible manner C4-2 or PEO1 cells were left 
untreated or treated with cisplatin and collected at the indicated 
time point.  Cells were lysed in CSK buffer and the cytoplasmic 
fraction was removed. The insoluble pellet was re-suspended in 
150 nM NETN buffer and sonicated.  The lysate was used for 
precipitation with either protein A beads alone or with an N-
terminal BRCA2 ab. 
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Conclusions 
 By performing a genome-wide loss of function screen in BRCA2 mutant 
ovarian cancer cells, we have identified that loss of the NuRD chromatin-
remodeling enzyme CHD4 promotes resistance to the chemotherapeutic agents 
cisplatin and partial resistance to the PARP inhibitor Olaparib (Figures 3-3, 3-10).  
CHD4 depletion in BRCA2 mutant cells promotes resistance to cisplatin 
independently of restored BRCA2 and canonical homologous recombination 
(Figures 3-7, 3-8, 3-28). CHD4 depletion in other cell lines with defects in the 
DDR, such as BRCA1, failed to promote cisplatin resistance suggesting that 
CHD4 depletion mediates resistance specifically in BRCA2 mutant cells (Figures 
3-13, 3-14, 3-15).  Consistent with CHD4 modulating therapeutic response in a 
BRCA2 mutant background, we identified that derived cisplatin resistant BRCA2 
mutant clones have low CHD4 protein expression (Figure 3-22). In addition, 
reduced CHD4 mRNA levels in BRCA2 mutant ovarian tumors correlates with 
poor patient response and overall survival (Figure 3-27).  Interestingly, CHD4 
depletion does not appear to mediate genetic reversion of BRCA2 or restoration 
of RAD51 based HR repair (Figures 3-7, 3-8).  CHD4 depletion in BRCA2 mutant 
cells likely occurs by a novel mechanism that is currently still under investigation 
and will be discussed in depth in the final conclusions and discussion chapter IV. 
  
 Given the roles of CHD4 and other NuRD complex members in the repair 
of DNA DSBs, it was unanticipated that CHD4 loss would rescue the cellular 
144
sensitivity associated with defects in BRCA2 mutant cells (Luo et al. 2000; 
Pegoraro et al. 2009; Smeenk et al. 2010; Sims & Wade 2011; Polo et al. 2010; 
Larsen et al. 2010; Urquhart et al. 2011). In our screen, however, the CHD4 gene 
was the most robust candidate (Figure 3-29). CHD4 depletion led to cisplatin 
resistance in several BRCA2-mutant cell lines (Figures 3-3, 3-5).  Notably, our 
screen did not identify additional NuRD complex members (Table 3-2). This 
result could stem from the fact that our screen was not saturating.  Alternatively, 
CHD4 may have unique functions aside from those associated with the NuRD 
complex.  Even though our screen did not identify other NuRD complex proteins, 
we independently examined two additional shRNAs targeting the DNA binding 
subunit of the NuRD complex, MBD2 (Lai & Wade 2011).  We found that MBD2 
depletion had the opposite effect of CHD4 depletion in BRCA2 mutant cells and 
caused reduced proliferation, reduced colony forming efficiency, and sensitivity to 
cisplatin (Figure 3-4).  Interestingly, while CHD4 depletion had no effect on 
MBD2 nuclear expression, the opposite was not true.  Depletion of MBD2 with 
either shRNA also reduced the nuclear expression of CHD4, yet as mentioned 
MBD2 depletion did not mediate resistance to cisplatin in this system (Figure 3-
4).  This finding suggests that aside from CHD4, the integrity of the remaining 
NuRD complex members must still be intact in order for CHD4 depletion to 
mediate cisplatin resistance.  
 
  In C.elegans and mammalian cells that are BRCA2 proficient, CHD4 loss 
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reduces proliferation, increases basal levels of γH2A.X, and increases cellular 
sensitivity to agents that induce DNA DSBs (Smeenk et al. 2010; Larsen et al. 
2010; Polo et al. 2010).  These outcomes could stem from the fact that CHD4 
depletion disrupts the G1 to S cell cycle transition and causes defects in the DNA 
damage induced G2/M checkpoint (Smeenk et al. 2010; Polo et al. 2010). To 
directly address the consequences of CHD4 loss relative to BRCA2, we 
examined CHD4 depletion in BRCA2 proficient and BRCA2 mutant cells. Upon 
CHD4 depletion in BRCA2 proficient cells, we similarly observed an increase in 
basal levels of γH2A.X, defects in proliferation, and sensitivity to agents that 
induce DNA damage (Figures 3-9, 3-10, 3-11, 3-12).  This not only corroborates 
previously published findings, but also functionally validates that my shRNAs 
targeting CHD4 produce similar outcomes in the DDR in a BRCA2 proficient 
background.  
  
 In contrast, the phenotypes generated by CHD4 depletion were 
ameliorated in BRCA2 mutant cells that retain a truncated form of BRCA2.  In 
BRCA2 mutant cells, CHD4 depletion did not affect colony-forming efficiency or 
induce γH2A.X (Figures 3-11, 3-12). Moreover, CHD4 depletion in BRCA2 
mutant cells enhanced resistance to not only cisplatin, but also the PARP 
inhibitor Olaparib, and the DNA DSB mimetic Zeocin (Figures 3-3, 3-10). One 
possible explanation for this phenomenon is that wild-type BRCA2 may normally 
function to activate the DDR upon loss of CHD4.  If BRCA2 indeed functions 
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downstream of CHD4, this could explain why CHD4 depletion does not activate 
the DDR in the context of BRCA2 mutations.  Given that truncated forms of 
BRCA2 are expressed in PEO1 and FA-D1 cells, this would also suggest that 
activation of the DDR upon CHD4 loss could be mediated through the far C-
terminal end of BRCA2.   
        
  However, the idea that BRCA2 depletion could rescue problems 
associated with CHD4 depletion was not supported by our subsequent 
experiments.  In particular, depletion of BRCA2 in concert with CHD4 depletion 
failed to alleviate the negative consequences of CHD4 depletion in C4-2 and 
U2OS cells and instead caused toxicity (Figures 3-17, 3-18).  We also further 
explored if the truncated BRCA2 species present in PEO1 cells was necessary 
for general viability or for the cisplatin resistance phenotype generated by CHD4 
depletion. Surprisingly, in untreated PEO1 cells, depletion of the truncated 
BRCA2 species induced a signaling response scored by induction of γH2A.X 
(Figure 3-19). This indicates that the truncated species contains some residual 
function that allows cells to cope with endogenous naturally occurring forms of 
genotoxic stress.  However, the increase in γH2A.X in BRCA2 depleted PEO1 
cells did not correspond with an increase in sensitivity to cisplatin when 
compared to non-silencing control cells (Figure 3-19).  This could be due to the 
function of an alterative repair pathway that could possibly compensate for loss 
of the truncated species in response to agents that directly induce DNA damage.  
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Interestingly, co-depletion of truncated BRCA2 and CHD4 in PEO1 cells partially 
negated the cisplatin resistance phenotype generated by CHD4 depletion alone 
(Figure 3-19).  This indicates that the mechanism of cisplatin resistance 
conferred by CHD4 depletion is at least partially dependent on the truncated 
BRCA2 species, which may gain function upon CHD4 depletion. 
 
 Given that the cisplatin resistance mediated by CHD4 depletion in PEO1 
cells was similar to BRCA2 restored C4-2 cells we examined if CHD4 depletion 
promoted BRCA2 genetic reversion to restore DNA repair by HR.  Analysis of 
RAD51 foci formation, a traditional functional indicator of active repair by HR, in 
cisplatin treated cells revealed induction of RAD51 foci in BRCA2 restored C4-2 
cells, but not in PEO1 cells expressing non silencing control or depleted of CHD4 
with two unique hairpins (Figure 3-7).  Examination of BRCA2 migration by SDS-
PAGE and subsequent western blotting with an antibody raised against the 
BRCA2 N-terminal revealed that BRCA2 was nuclear, but still truncated in CHD4 
depleted cells (Figure 3-8).  The BRCA2 band in CHD4 depleted cells migrated 
similar to the form in PEO1 parental cells when compared to full length BRCA2 in 
C4-2 restored cells.  Taken together, these studies suggest that CHD4 depletion 
in BRCA2 mutant PEO1 cells does not promote cisplatin resistance through 
restored BRCA2.  
  
 In BRCA2 mutant ovarian tumors, similar to the PEO1 cells used in our 
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study, BRCA2 mutations do not typically nullify expression of BRCA2, but instead 
are governed by frameshifts and premature stop codons that predict truncated 
BRCA2 species (Table 3-1).  In addition, unlike BRCA1, the promoter of BRCA2 
is not thought to undergo methylation induced gene silencing (Collins et al. 1997; 
Matros et al. 2005).  Using mRNA derived from BRCA2 mutant tumors and 
information regarding patient response to therapy in the clinic we found that 
elevated CHD4 mRNA levels significantly correlated with improved patient 
response to therapy.  We also found that elevated CHD4 mRNA levels correlated 
with improved overall survival in patients (Figure 3-27).  Thus, CHD4 mRNA 
levels could serve as a biomarker to predict patient response to therapy 
specifically in BRCA2 mutant ovarian tumors.   
  
 CHD4 depletion in BRCA2 mutant PEO1 ovarian cancer cells mediated 
resistance to other drugs in addition to cisplatin.  Our research suggests that 
BRCA2 mutant tumors with low CHD4 may be sensitive to other therapies. In 
particular, cross-examination of BRCA2 mutant cells with additional drugs 
identified that the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) 
caused toxicity selectively in BRCA2 mutant CHD4 depleted cells compared to 
control (Figure 3-16).  Importantly, TSA treatment also caused toxicity to BRCA2 
mutant derived cisplatin resistant clones that lost CHD4 expression (Figure 3-24).  
In the BRCA2 restored clone C4-2, CHD4 depleted cells were not selectively 
more sensitive to treatment with TSA as compared to control cells (Figure 3-16).  
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The HDAC inhibitor TSA may therefore have potential as an alternative therapy 
for BRCA2 mutant tumors with reduced CHD4 expression.   
 
 Interestingly, purification of the NuRD complex nearly a decade ago from 
several species revealed the direct association of the histone deacetylases 
HDAC1 and HDAC2 (Tong et al. 1998; Wade et al. 1998; Zhang et al. 1998).  
These subunits catalyze histone deacetylation and are thought to be associated 
with transcriptional repression (Tong et al. 1998; Ng & Bird 2000).  However, 
adding to the complexity, CHD4 association with histone deacetylases and 
methyl transferases can also result in transcriptional activation (Shimono et al. 
2003; Williams et al. 2004; Denslow & Wade 2007).  Laser micro-irradiation of 
human U2OS cells revealed that HDAC1 is transiently recruited to DNA DSBs in 
a manner partially dependent on CHD4 (Polo, 2010).  In this study, CHD4 
depletion mediates sensitivity to the HDAC inhibitor TSA in the presence of 
BRCA2 mutations.  We did not examine if CHD4 depletion effects nuclear 
expression or the deacetylase activity of HDAC1 or HDAC2, but the finding that 
TSA treatment is toxic to CHD4 depleted cells suggests that these HDAC 
dependent processes may still be functional and aid in the survival of BRCA2 
mutant cells upon loss of CHD4.   
  
 In vivo studies in a BRCA2 mutant mouse model of ovarian cancer would 
be best suited to determine if TSA has therapeutic potential in tumors with 
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reduced CHD4 expression.  To date, a BRCA1 mutant mouse model of ovarian 
cancer exists that is also driven by loss of the p53 tumor suppressor (Xing & 
Orsulic 2006).  However, our study demonstrates that CHD4 depletion mediated 
toxicity in BRCA1 mutant cells and CHD4 expression levels had no correlative 
effect on progression free survival in BRCA1 mutant tumors (Figures 3-13, 3-14, 
3-26).  Thus, future studies examining the therapeutic response of BRCA2 
mutant tumors would greatly benefit from a mouse model that expresses mutant 
BRCA2 in the ovarian epithelium.     
 
 Altogether, this study provides an understanding of how BRCA2 mutant 
cells can gain resistance to cisplatin independently of BRCA2 genetic reversion 
and restoration of HR.  Importantly, loss of CHD4 expression promotes 
resistance to cisplatin and other drugs and could serve as a potential biomarker 
to predict patient response in the clinic.  Given that treatment with the HDAC 
inhibitor TSA causes selectively toxicity to CHD4 depleted BRCA2 mutant cells, 
TSA may be a potential therapeutic alternative for BRCA2 patients presenting 
ovarian tumors with low CHD4 expression. 
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Materials and Methods: 
 
Cell Lines 
Ovarian cancer cell lines PEO1, C4-4, C4-11, C4-13, and C4-2 were grown in 
DMEM with 10% FBS and 1% Glutmax, CAPAN1, FA-D1, XP-F, PD20, and FA-J 
patient cells were grown in DMEM with 15% FBS.  We thank Toshi Taniguchi for 
PEO1 series cells and Orlando Scharer for XP-F cells. 
 
shRNA Screen 
The human shRNAmir pGIPZ library (release 6.0; Open Biosystems) was 
generously obtained through the UMass Medical School shRNA library core 
facility. Lentiviral pools were generated and used to transduce PEO1 cells as 
described at an MOI of 0.2 (Gazin et al., 2007). Cells that bypassed 2 cycles of 2 
uM cisplatin treatment (enough to induce ~100% lethality in shNSC pool) 
underwent cellular proliferation to form colonies.  Colonies were pooled and 
expanded, and the shRNAs identified by sequence analysis as previously 
described (Gazin et al., 2007). For validation, individual knockdown cell lines 
were generated by stable transduction of 6×104 cells with a single shRNA. 
 
RNA Interference 
The packaging cell line 293TL was used to produce lentiviral particles containing 
pGIPZ or pLKO.1 vectors. Cells were transfected with 1:1:2 ug of DNA packaging 
versus insert using Effectene® transfection reagent (Qiagen) 48 h prior to 
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harvesting retroviral or lentiviral supernatants. Supernatants were filtered and 
added to recipient cell lines with 1 ug/ml polybrene. Cells infected with shRNA 
vectors were selected with either puromycin (pGIPZ, pLKO.1). For shRNA-
mediated silencing the mature antisense was used for pGIPZ CHD4-1 5'-
ATTCATAGGATGTCAGCAG -3', for CHD4-2 5'-TTAGTTCTGTCTTGGAGGG -
3'and for pLKO.1 CHD4-1 5'-GCTGCTGACATCCTATGAATT-3', for CHD4-2 5'-
GCTGACACAGTTATTATCTAT-3'. 
 
Immunofluorescence 
Cells were fixed for 10 min with 3% paraformaldehyde/2% sucrose in phosphate 
buffered saline (PBS) and permeabilized for 5 min with 0.5% Triton X-100.  
Coverslips were rinsed 3x in 1xPBS prior to each step.  For cocktails of primary 
and secondary antibody staining, cells were incubated for 40 min. each in a 
humid chamber, face down on a 100uL meniscus of Abs diluted in 3%BSA in 
PBS.  Primary Abs used were anti-RAD51 (1:500 X), anti-gamma H2AX (1:500 
Y). Secondary Abs used were Rhodamine Red-X conjugated AffiniPure Goat 
anti-rabbit IgG and fluorescein (FITC)-conjugated AffiniPure Goat anti-mouse IgG 
(Jackson Immuno-research Laboratories Inc). Coverslips were mounted on slides 
using Vectashield® mounting media with DAPI (Vecta laboratories, Inc) and 
analyzed on a fluorescence microscope (Leica DM 5500B) with a Qimaging 
Retiga 2000R Fast 1394 camera. 
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Western Blot 
Cells were harvested and lysed in 150 mM NETN lysis buffer (20mM Tris (pH 
8.0), 150 mM NaCl, 1mM EDTA, 0.5% NP-40, 1mM phenylmethylsulfonyl 
fluoride, and 1x protease inhibitor cocktail) for 30 minutes on ice.  Cell extracts 
were clarified by centrifugation at 14,000 rpm, protein was quantified by Bradford 
assay, and lysates were boiled in SDS loading buffer.  Nuclear extracts were 
prepared with a Nuclear Extraction Kit (ThermoFisher) and Proteins were 
separated by SDS-PAGE on 4-12% bis Tris or 3-8% Tris Acetate gels (Novex, 
Life Technologies) and electrotransferred onto nitrocellulose membranes.  For 
cellular fractionation used for immuno-precipitation, cells were pelleted and the 
cytoplasmic fraction was removed with incubation for 5 minutes in CSK buffer.  
The remaining pellet was washed 2x in CSK buffer and then re-solubilized in 150 
nM NETN and sonicated with 3- 2 second pulses.  The lysate was collected as 
the nuclear fraction after centrifugation and was pre-cleared for 1 hr at 4 degrees 
Celsius with protein A beads prior to Bradford analysis, overnight immune-
precipitation, and SDS-PAGE.  Membranes were blocked in 5% milk diluted in 
PBS.  Antibodies used for Western blot analysis included anti-Bactin (1:5000 
Sigma), anti-MCM7  (1:1000 Abcam), anti-CHD4 (1:1000 Abcam), anti-MBD2 
(1:500 Santa Cruz), anti-BRCA2 N-terminal ab (1:1000 Abcam), anti-Rad51 
3C10 (1:500 Millipore), anti-Rad51 H-92 (1:1000 Santa Cruz), anti-phosphS138 
H2A.X (1:500 Bethyl), and anti-Cleaved Caspase-3 Asp175 (1:500 Cell 
Signaling).  Membranes were washed and incubated with horseradish 
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peroxidase-linked secondary antibodies (Amersham 1:5000), and detected by 
chemiluminescence (Ambersham).   
 
 
FACS Analysis 
Cells were cultured to ~ 60% confluency were left untreated or treated with 0.5 
uM Cisplatin before collecting and washing with 1x PBS and fixing with 90% 
methanol. Cells were labeled with propidium iodide prior to analysis on a FACS 
Caliber flow cytometer (Becton-Dickinson) performed at the University of 
Massachusetts Medical School flow cytometry core facility using Cellquest 
software.  
 
DNA constructs 
GFP-CHD4 was expressed in PEO1, C4-2, and C4-4 cells as described in (Polo, 
2010) and was a generous gift from Stephen Jackson.  Cells were harvested 48 
hours after transient transfection for analysis of GFP expression by western 
blotting.  
 
Statistics 
All quantitative data were collected from experiments performed in triplicate, and 
expressed as mean ± s.d.  Differences between experimental groups were 
calculated using a two-tailed, unpaired student t-test using Excel Microsoft or 
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Graphpad.  Where shown, asterisks denote significance *p ≤0.05, **p ≤0.01, ***p 
≤0.005.         
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CHAPTER IV:  
 
Final Summary and Discussion 
 
  In my series of investigations dissecting the roles of tumor suppressor 
proteins in the DDR I have revealed (I) a novel function for the DNA helicase 
FANCJ in protecting the genome against UV irradiation and (II) a role for the 
chromatin remodeling factor CHD4 in modulating the cellular response to DNA 
damage in BRCA2 mutant cells.  Though these two separate investigations were 
not directly linked, they provide a better understanding of how tumor suppressor 
proteins function in the DDR. 
 
 In my first investigation I identified that both NER and MMR proteins 
support the localization of FANCJ at sites of UV-induced lesions to ensure a 
checkpoint response during S phase of the cell cycle (Figures 2-2-2-5, 2-7-2-10, 
2-15-2-19).  The MMR proteins initially recruit FANCJ to DNA lesions and further 
accumulation requires dual incision by the NER endonucleases XPF and XPG 
(Figures 2-2-2-5, 2-7-2-10).  Consistent with FANCJ and MMR functioning in a 
common pathway, I found that FANCJ or MMR deficiency alone or in 
combination generated similar defects in the checkpoint response and in the 
elimination of UV induced DNA lesions (Figure 2-20).  Interestingly, FANCJ 
depletion did not result in UV-induced toxicity. However, my analysis revealed an 
important role for FANCJ in suppressing UV-induced mutations, especially C>T 
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point mutations, the most prevalent type of mutation found in melanoma (Figure 
2-26, Table 2-1) (Drobetsky et al. 1987; Berger et al. 2010; Hodis et al. 2012).   
 
By searching sequenced melanoma genome databases such as 
cBioPortal and the Catalogue of Somatic Mutations in Cancer (CoSMiC) I 
discovered mutations in several proteins investigated in my functional assays, 
namely FANCJ, MSH2, MSH6, MLH1, and PMS2 (Tabel 2-2) (Cerami et al. 
2012; Gao et al. 2013; Forbes et al. 2011).  Importantly, while about 5.7 % of the 
melanomas carried heterozygous FANCJ mutations, these tumors did not co-
segregate with the MMR associated mutations (Cerami et al. 2012; Gao et al. 
2013).  Given that my co-depletion studies of FANCJ and MSH2 suggested these 
factors function in a common pathway in response to UV irradiation, the finding 
that MMR and FANCJ associated mutations do no co-segregate supports this 
notion and suggests that  “one-hit’ could be sufficient to inactivate this pathway. 
 
The majority of FANCJ melanoma associated mutations target important 
domains including the helicase domain, the Fe-S domain, and helicase boxes III, 
IV, and V (Figure 2-29).  Importantly, some of the mutations have been detected 
previously in other types of cancer. The FANCJP47 amino acid change was also 
targeted in hereditary breast cancer and was demonstrated to be ATPase and 
helicase inactive in in vitro assays (Cantor et al. 2004).  The splice variant 
FANCJR831 is the same allele found in Fanconi anemia patients and eliminates 
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conserved helicase boxes required for enzyme function (Cantor et al. 2004; 
Cantor & Guillemette 2011; Gupta et al. 2005). 
 
Although I did not examine the FANCJ melanoma associated mutations in 
functional assays, since the majority of these mutations targeted the 
ATPase/helicase domain I ectopically expressed the catalytically inactive 
FANCJK52R mutant in U2OS cells. Overexpression of the FANCJK52R mutant 
determined that loss of FANCJ ATPase/helicase/translocase activity disrupts the 
clearance of UV induced lesions in a dominant negative manner.  Interestingly, 
FANCJK52R expression had no significant effect on RPA phosphorylation at the 
time point examined (Figure 2-30). Therefore, while expression of the enzyme 
inactive mutant dominantly disrupted lesion repair, it appears that loss of FANCJ 
expression is required to disrupt checkpoint activation in response to UV 
irradiation. 
 
Future studies that express FANCJ melanoma associated mutants in non-
transformed melanocytes would be informative to determine if these FANCJ 
species truly destabilize the genome to support melanoma transformation in the 
face of UV irradiation.  CRISPR/Cas-mediated genome editing could be used to 
express FANCJ melanoma associated mutations and examine transformation 
potential in melanocytes (Cong et al. 2013).  It would also be interesting to 
examine FANCJ melanoma associated mutations and the latency of melanocyte 
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transformation in the context of oncogenic BRAF or RAS mutations, given the 
large number of melanomas harboring mutations in these genes (Brose et al. 
2002; Davies et al. 2002; Omholt et al. 2003; Pollock et al. 2003; Wan et al. 
2004).  Paradoxically, BRAFV600E mutations are also present in benign 
melanocytic nevi and have been shown to induce cellular senescence (Pollock et 
al. 2003).  This brings attention to the fact that additional genetic alterations must 
be required in order to promote cellular transformation.  A loss of function screen 
performed to identify factors that could escape BRAFV600E induced senescence 
did not identify FANCJ, but the screen was not saturating (Wajapeyee et al. 
2008).  Taken together, although my findings support the notion that FANCJ 
could be a suppressor of cancers induced by UV irradiation, the function of 
FANCJ as a tumor suppressor in melanoma still remains to be determined. 
 
In the second part of my investigation I performed a genome wide shRNA 
screen to identify factors that modulate cisplatin resistance in a BRCA2 mutant 
background (Figure 3-2).  The most robust target identified from my screen was 
the NuRD complex member CHD4 (Figure 3-3).  Examination of CHD4 depletion 
in other cells lines with known defects in the DDR, such as BRCA1, did not 
rescue cellular sensitivity to cisplatin suggesting that rescue is specific to a 
BRCA2 mutant background (Figures 3-13-3-15).  In addition, depletion of second 
unique NuRD complex member, MBD2, in BRCA2 mutant cells did not promote 
resistance to cisplatin (Figure 3-4). This further suggests that cisplatin resistance 
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in BRCA2 mutant cells is not mediated by general loss of the NuRD complex, but 
is specifically mediated by loss of CHD4.  Importantly, in BRCA2 mutant ovarian 
tumors CHD4 expression could serve as a prognostic factor.  Patients with high 
CHD4 expression have significantly improved progression free survival and 
improved overall survival (Figure 3-27). 
 
As CHD4 has been shown to function in the DDR, I was intrigued to 
examine the loss of CHD4 in both BRCA2 proficient and BRCA2 mutant 
backgrounds (Smeenk et al. 2010; Larsen et al. 2010; Polo et al. 2010). BRCA2 
genetic reversion is one known mechanism that promotes cisplatin resistance in 
cell culture and in patients (Sakai et al. 2008; Edwards et al. 2008; Sakai et al. 
2009).  Using BRCA2 mutant PEO1 cells and their revertant counterpart, BRCA2 
restored C4-2 cells I was able to depleted CHD4 in both backgrounds (Sakai et 
al. 2009).  Upon examination of CHD4 depletion, I found that the negative 
consequences associated with proliferation and toxicity to DNA damaging agents 
in the BRCA2 proficient cells were ameliorated in the BRCA2 mutant cells 
(Figures 3-10-3-12).   
 
These findings led me to hypothesize that BRCA2 was functioning 
downstream of CHD4 and activating a DDR upon CHD4 depletion.  However, co-
depletion of CHD4 and BRCA2 in C4-2 and U2OS cells did not alleviate the 
phenotypes associated with CHD4 depletion (Figures 3-17, 3-18). It is possible 
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that BRCA2 is not functioning downstream of CHD4 or that BRCA2 has other 
essential recombination-based roles required for viability that when lost promote 
cell death regardless of whether or not CHD4 is expressed.  
 
I also discovered that the truncated form of BRCA2 was required for PEO1 
cells to mediate cisplatin resistance upon CHD4 depletion (Figure 3-19).  It is 
possible that the truncated form of BRCA2 may gain a new function upon CHD4 
depletion.  The truncated BRCA2 in PEO1 cells retains several important 
domains including the binding domain for the partner and localizer of BRCA2 
(PALB2), four BRC RAD51 binding domains, the transcriptional activation 
domain, and the binding domain for the oncogene EMSY which potentially 
suppresses the transcriptional activation of BRCA2 (Hughes-Davies et al. 2003; 
Sakai et al. 2009; Jensen 2013).  In response to cisplatin I confirmed that the 
truncated form of BRCA2 is still capable of binding RAD51 in a DNA damage 
inducible manner (Figure 3-29).  This again suggests that truncated BRCA2 
retains residual function. Experiments using an N-terminal BRCA2 antibody or an 
antibody raised against a tagged version of truncated BRCA2 could isolate novel 
species associating with truncated BRCA2 in cells isogenic for CHD4 expression.  
This approach could shed light on the protein interactions or potential new 
functions that truncated BRCA2 gains upon CHD4 depletion to mediate cisplatin 
resistance. 
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As CHD4 depleted BRCA2 mutant cells were cross-resistant to other DNA 
damaging agents aside from cisplatin, I further screened FDA approved drugs 
and discovered that these cells were selectively sensitive to the histone 
deacetylase inhibitor Trichostatin A (Figure 3-16).  This was initially surprising 
given that the histone deacetylases HDAC1 and HDAC2 directly associate with 
the NuRD complex that also contains CHD4 (Tong et al. 1998; Wade et al. 1998; 
Zhang et al. 1998).  Interestingly, this suggests that CHD4 depleted cells retain 
histone deacetylase activity despite loss of this NuRD complex member. 
Inhibiting histone deacetylase activity is thought to relax chromatin by allowing 
retention of the acetyl moieties on histones.  Changes in chromatin structure 
upon HDAC inhibition are also likely to effect transcriptional profiles fostering re-
programming of the transcriptome.   Interestingly, the NuRD complex has been 
associated with transcriptional repression and activation (Tong et al. 1998; Ng & 
Bird 2000; Shimono et al. 2003; Williams et al. 2004; Denslow & Wade 2007).  It 
is possible that CHD4 depletion could facilitate transcriptional re-programming 
and CHD4 depleted cells could be completely reliant on their new transcriptional 
program for survival.  HDAC inhibition could promote toxicity in CHD4 depleted 
cells by perturbing their transcriptional profile.  It is also possible that changes in 
the transcriptome of CHD4 depleted cells could be responsible for mediating the 
resistance to DNA damaging agents observed in the BRCA2 mutant background.  
To determine if the mechanism of cisplatin resistance in CHD4 depleted BRCA2 
mutant cells is dependent on transcription I could transiently treat cells with 
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transcriptional inhibitors prior to or during the course of cisplatin treatment and 
analyze survival.  
 
If CHD4 depleted cells gain resistance by a mechanism dependent on 
transcription, it would be useful to perform microarrays or whole transcriptome 
shotgun sequencing  (RNA-seq) on BRCA2 mutant cells containing stable 
hairpins targeting a non-silencing control or CHD4.  These types of experiments 
could yield a dozen or several hundred potential candidates that would require 
careful validation.  As CHD4 depletion promotes cisplatin resistance in several 
BRCA2 mutant cell lines, RNA-seq could be performed on cells depleted of 
CHD4 versus non-silencing control in different BRCA2 mutant backgrounds.  The 
resulting data sets could be cross-examined in an attempt to narrow down the list 
of potential candidates.   
 
Another interesting aspect that could be explored is the transcriptional 
transactivation activity contained within the N-terminal of truncated BRCA2 (Fuks 
et al. 1998; Marmorstein et al. 1998; Nordling et al. 1998; Yoshida & Miki 2004).  
With a highly specific antibody, one could perform chromatin immunoprecipitation 
sequencing (ChIP-Seq) on BRCA2 mutant cells depleted of CHD4 versus non-
silencing control. This would help determine if CHD4 depletion alters the 
positions of truncated BRCA2 binding in the genome.   If changes occur upon 
CHD4 depletion, the regions bound by BRCA2 could be cross-examined with 
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RNA-Seq data sets generated from CHD4 “isogenic” cells mentioned above.  
Cross-examination of BRCA2 ChIP-Seq and RNA-seq data sets could potentially 
identify transcriptional changes mediated by truncated BRCA2 upon CHD4 
depletion.   Conversely, since BRCA2 is directly involved in DNA repair, it is likely 
to be ubiquitously bound to many regions of the genome.  ChIP-Seq experiments 
performed with a BRCA2 antibody could therefore be very noisy and useless in 
identifying BRCA2 dependent transcriptional targets.  In any case, one would first 
need to determine if the mechanism of cisplatin resistance in CHD4 depleted 
BRCA2 mutant cells is dependent on transcription before RNA-Seq or BRCA2 
ChIP–Seq experiments would be warranted.  
 
Taken together, these studies have allowed me to better appreciate the 
difficulties associated with isolating one gene and studying its outcome in the 
context of DNA repair or drug resistance.  In the case of the shRNA screen I was 
able to identify several genes that modulate cisplatin resistance in the context of 
BRCA2 mutations (Figure 3-28, Table 3-2).  While acquiring the list of >100 
genes was exciting, it also proved to be a daunting task for validation.  In these 
types of screens one hopes to ultimately elucidate at least some aspect of the 
problem they are trying to study and I feel that I have accomplished that.  
Whether taking a candidate approach as in my first investigation or an unbiased 
approach as in my second investigation, I have realized that biological processes 
are always extremely complex.  Once I understand a specific molecular process I 
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am always led to question many others.  What I can trust is that these curiosities 
will always drive research forward. 
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